CN116535381B - Cationic lipid compound having five-membered ring acetal structure, composition containing same and use - Google Patents
Cationic lipid compound having five-membered ring acetal structure, composition containing same and use Download PDFInfo
- Publication number
- CN116535381B CN116535381B CN202310821280.1A CN202310821280A CN116535381B CN 116535381 B CN116535381 B CN 116535381B CN 202310821280 A CN202310821280 A CN 202310821280A CN 116535381 B CN116535381 B CN 116535381B
- Authority
- CN
- China
- Prior art keywords
- compound
- composition
- formula
- pharmaceutically acceptable
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Cationic lipid compound Chemical class 0.000 title claims abstract description 208
- 239000000203 mixture Substances 0.000 title claims abstract description 172
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 186
- 150000003839 salts Chemical class 0.000 claims abstract description 85
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 57
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 51
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 51
- 150000002632 lipids Chemical class 0.000 claims description 127
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 108020004999 messenger RNA Proteins 0.000 claims description 54
- 230000007935 neutral effect Effects 0.000 claims description 42
- 125000002947 alkylene group Chemical group 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 229920000642 polymer Polymers 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 22
- 229950004354 phosphorylcholine Drugs 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000002105 nanoparticle Substances 0.000 claims description 20
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 108020004459 Small interfering RNA Proteins 0.000 claims description 16
- 229920002477 rna polymer Polymers 0.000 claims description 16
- ZBHSAYWIYAVUOP-UHFFFAOYSA-N 2-(benzylamino)-1-[3-(trifluoromethyl)phenyl]ethanol Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(O)CNCC1=CC=CC=C1 ZBHSAYWIYAVUOP-UHFFFAOYSA-N 0.000 claims description 15
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 13
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 11
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 229930182558 Sterol Natural products 0.000 claims description 7
- 150000003432 sterols Chemical class 0.000 claims description 7
- 235000003702 sterols Nutrition 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 6
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 6
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims description 6
- ATHVAWFAEPLPPQ-LNVKXUELSA-N [3-octadecanoyloxy-2-[(z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC ATHVAWFAEPLPPQ-LNVKXUELSA-N 0.000 claims description 6
- 150000001783 ceramides Chemical class 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 229960001334 corticosteroids Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010037742 Rabies Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 230000002452 interceptive effect Effects 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 3
- LGJMUZUPVCAVPU-ANOYILKDSA-N (3s,8r,9s,10s,13r,14s,17r)-17-[(2r,5s)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical class C1CC2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 LGJMUZUPVCAVPU-ANOYILKDSA-N 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 3
- MHUWZNTUIIFHAS-DSSVUWSHSA-N 1,2-dioleoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-DSSVUWSHSA-N 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 3
- 241000204432 Candidatus Sodalis pierantonius str. SOPE Species 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 3
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 208000027032 Renal vascular disease Diseases 0.000 claims description 3
- 208000000705 Rift Valley Fever Diseases 0.000 claims description 3
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 3
- 208000003152 Yellow Fever Diseases 0.000 claims description 3
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 3
- 235000004420 brassicasterol Nutrition 0.000 claims description 3
- 235000000431 campesterol Nutrition 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 150000001982 diacylglycerols Chemical class 0.000 claims description 3
- 125000005265 dialkylamine group Chemical class 0.000 claims description 3
- 150000001985 dialkylglycerols Chemical class 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 150000002137 ergosterols Chemical class 0.000 claims description 3
- XGVJWXAYKUHDOO-UHFFFAOYSA-N galanthidine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1=CC(O)C3O XGVJWXAYKUHDOO-UHFFFAOYSA-N 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- XGVJWXAYKUHDOO-DANNLKNASA-N lycorine Chemical compound C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2C1=C[C@H](O)[C@H]3O XGVJWXAYKUHDOO-DANNLKNASA-N 0.000 claims description 3
- KQAOMBGKIWRWNA-UHFFFAOYSA-N lycorine Natural products OC1C=C2CCN3C2C(C1O)c4cc5OCOc5cc34 KQAOMBGKIWRWNA-UHFFFAOYSA-N 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- HSUGDXPUFCVGES-UHFFFAOYSA-N n-tetradecyltetradecan-1-amine Chemical compound CCCCCCCCCCCCCCNCCCCCCCCCCCCCC HSUGDXPUFCVGES-UHFFFAOYSA-N 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 150000008103 phosphatidic acids Chemical class 0.000 claims description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 208000015670 renal artery disease Diseases 0.000 claims description 3
- 235000015500 sitosterol Nutrition 0.000 claims description 3
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 3
- 229940083492 sitosterols Drugs 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 235000016831 stigmasterol Nutrition 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 229940096998 ursolic acid Drugs 0.000 claims description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 3
- 235000004835 α-tocopherol Nutrition 0.000 claims description 3
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 abstract description 54
- 150000001204 N-oxides Chemical class 0.000 abstract description 50
- 210000004027 cell Anatomy 0.000 description 82
- 238000001890 transfection Methods 0.000 description 82
- 230000015572 biosynthetic process Effects 0.000 description 64
- 238000003786 synthesis reaction Methods 0.000 description 62
- 230000001976 improved effect Effects 0.000 description 46
- BGNVBNJYBVCBJH-UHFFFAOYSA-N SM-102 Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCC(OCCCCCCCCCCC)=O BGNVBNJYBVCBJH-UHFFFAOYSA-N 0.000 description 43
- 125000002091 cationic group Chemical group 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 210000000952 spleen Anatomy 0.000 description 37
- 229940125904 compound 1 Drugs 0.000 description 36
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 35
- NTCPGTZTPGFNOM-UHFFFAOYSA-N 4-[2-(methylamino)propyl]benzene-1,2-diol Chemical compound CNC(C)CC1=CC=C(O)C(O)=C1 NTCPGTZTPGFNOM-UHFFFAOYSA-N 0.000 description 34
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 34
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 239000005022 packaging material Substances 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 23
- 231100000135 cytotoxicity Toxicity 0.000 description 22
- 230000003013 cytotoxicity Effects 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 239000004055 small Interfering RNA Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000002994 raw material Substances 0.000 description 15
- 239000002502 liposome Substances 0.000 description 14
- 238000010189 synthetic method Methods 0.000 description 14
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000001241 acetals Chemical group 0.000 description 12
- 230000003833 cell viability Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 6
- 229960000640 dactinomycin Drugs 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 108010092160 Dactinomycin Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- XWSJVWPWQMAZQM-UHFFFAOYSA-N heptadecan-9-yl octanoate Chemical compound CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCC XWSJVWPWQMAZQM-UHFFFAOYSA-N 0.000 description 4
- PQYGSSYFJIJDFK-UHFFFAOYSA-N heptyl ketone Chemical compound CCCCCCCC(=O)CCCCCCC PQYGSSYFJIJDFK-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229940126586 small molecule drug Drugs 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229930192392 Mitomycin Natural products 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001917 fluorescence detection Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- ZNLHWEDEIKEQDK-UHFFFAOYSA-N 5-chloropentanal Chemical compound ClCCCCC=O ZNLHWEDEIKEQDK-UHFFFAOYSA-N 0.000 description 2
- LCSCNPZJBMHOJH-UHFFFAOYSA-N 7-(1,3-benzodioxol-5-yl)-6-hydroxy-5-methoxy-2,2-dimethylpyrano[3,2-g]chromen-8-one Chemical compound C1=C2OCOC2=CC(C=2C(=O)OC=3C=C4OC(C)(C)C=CC4=C(C=3C=2O)OC)=C1 LCSCNPZJBMHOJH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- OSRXPYBONSVZQX-UHFFFAOYSA-N 8,8-dimethoxypentadecane Chemical compound CCCCCCCC(OC)(OC)CCCCCCC OSRXPYBONSVZQX-UHFFFAOYSA-N 0.000 description 2
- DETKMHVWNMOSRN-UHFFFAOYSA-N 8-bromooctanal Chemical compound BrCCCCCCCC=O DETKMHVWNMOSRN-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 108010026389 Gramicidin Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 101150038500 cas9 gene Proteins 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 2
- 229960002694 emetine Drugs 0.000 description 2
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000005313 fatty acid group Chemical group 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- WTJKUFMLQFLJOT-UHFFFAOYSA-N heptadecan-9-one Chemical compound CCCCCCCCC(=O)CCCCCCCC WTJKUFMLQFLJOT-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- YUPOCHDBBHTUBJ-UHFFFAOYSA-N nonadecan-10-one Chemical compound CCCCCCCCCC(=O)CCCCCCCCC YUPOCHDBBHTUBJ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 125000005474 octanoate group Chemical group 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 1
- IHNKQIMGVNPMTC-UHFFFAOYSA-N (2-hydroxy-3-octadecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C IHNKQIMGVNPMTC-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RRQWVJIFKFIUJU-UHFFFAOYSA-N 1-bromooctadec-9-ene Chemical compound CCCCCCCCC=CCCCCCCCCBr RRQWVJIFKFIUJU-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- AMCAQENHDQIBBO-UHFFFAOYSA-N 2-(5-bromopentyl)oxirane Chemical compound BrCCCCCC1CO1 AMCAQENHDQIBBO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- SSZWWUDQMAHNAQ-UHFFFAOYSA-N 3-chloropropane-1,2-diol Chemical compound OCC(O)CCl SSZWWUDQMAHNAQ-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- GNYDYUQVALBGGZ-UHFFFAOYSA-N 7-bromohept-1-ene Chemical compound BrCCCCCC=C GNYDYUQVALBGGZ-UHFFFAOYSA-N 0.000 description 1
- FLQCCGGKQYPVPH-UHFFFAOYSA-N 7-bromoheptane-1,2-diol Chemical compound OCC(O)CCCCCBr FLQCCGGKQYPVPH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- MSLUDHUJFACMKQ-UHFFFAOYSA-N 8-bromo-1,1-dioctoxyoctane Chemical compound BrCCCCCCCC(OCCCCCCCC)OCCCCCCCC MSLUDHUJFACMKQ-UHFFFAOYSA-N 0.000 description 1
- GMXIEASXPUEOTG-UHFFFAOYSA-N 8-bromooctan-1-ol Chemical compound OCCCCCCCCBr GMXIEASXPUEOTG-UHFFFAOYSA-N 0.000 description 1
- NQOWMUPUQYQVOF-UHFFFAOYSA-N 9,9-dimethoxyheptadecane Chemical compound C(CCCCCCC)C(OC)(OC)CCCCCCCC NQOWMUPUQYQVOF-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- LWFDUMPGOAKHKC-UHFFFAOYSA-N C1=CC=C2C=C(C(=O)C(C(O)=C3O)=O)C3=CC2=C1 Chemical compound C1=CC=C2C=C(C(=O)C(C(O)=C3O)=O)C3=CC2=C1 LWFDUMPGOAKHKC-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000963438 Gaussia <copepod> Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 235000021506 Ipomoea Nutrition 0.000 description 1
- 241000207783 Ipomoea Species 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 102100031900 Neogenin Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- ROIHYOJMCBKEER-UHFFFAOYSA-N Stenine Natural products C12C3CCN2CCCCC1C(CC)C1C3C(C)C(=O)O1 ROIHYOJMCBKEER-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
- 102100035000 Thymosin beta-4 Human genes 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ROIHYOJMCBKEER-KRJCKNDRSA-N ac1l42y2 Chemical compound C([C@H]1[C@@H]23)CN3CCCC[C@@H]2[C@@H](CC)[C@H]2[C@@H]1[C@H](C)C(=O)O2 ROIHYOJMCBKEER-KRJCKNDRSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- SBFUTUNSWVKMSF-UHFFFAOYSA-N docos-9-en-1-ol Chemical compound CCCCCCCCCCCCC=CCCCCCCCCO SBFUTUNSWVKMSF-UHFFFAOYSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- QEAKPURUBFBQGD-UHFFFAOYSA-N ethyl 13,14-dihydroxydocosanoate Chemical compound CCCCCCCCC(O)C(O)CCCCCCCCCCCC(=O)OCC QEAKPURUBFBQGD-UHFFFAOYSA-N 0.000 description 1
- VCWDSCBRVHLTOD-UHFFFAOYSA-N ethyl 9,10-dihydroxyoctadecanoate Chemical compound CCCCCCCCC(O)C(O)CCCCCCCC(=O)OCC VCWDSCBRVHLTOD-UHFFFAOYSA-N 0.000 description 1
- WFZQLUSOXHIVKL-UHFFFAOYSA-N ethyl docos-13-enoate Chemical compound CCCCCCCCC=CCCCCCCCCCCCC(=O)OCC WFZQLUSOXHIVKL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- WRCUIPZUTXISRZ-UHFFFAOYSA-N heptadecan-9-yl 8-(2-hydroxyethylamino)octanoate Chemical compound OCCNCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC WRCUIPZUTXISRZ-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 108010076969 neogenin Proteins 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N octadec-9-en-1-ol Chemical compound CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- VRAOQOFWZFIOSZ-UHFFFAOYSA-N osmium potassium Chemical compound [K].[Os] VRAOQOFWZFIOSZ-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 229940006509 strontium-89 Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 108010079996 thymosin beta(4) Proteins 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960001266 typhoid vaccines Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
Abstract
The invention provides a cationic lipid compound with a five-membered ring acetal structure, which is a compound shown in a formula (I) or N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof. Also provided are compositions comprising the foregoing compounds and their use for delivering therapeutic or prophylactic agents.
Description
Technical Field
The invention belongs to the field of medicines. The invention particularly relates to a cationic lipid compound with a five-membered ring acetal structure, a composition containing the cationic lipid compound and application thereof.
Background
Efficient targeted delivery of biologically active substances such as small molecule drugs, polypeptides, proteins and nucleic acids, especially nucleic acids, is a persistent medical challenge. Nucleic acid therapeutics face significant challenges due to low cell permeability and high sensitivity to degradation by certain nucleic acid molecules, including RNA.
Compositions, liposomes and liposome complexes (lipoplex) containing cationic lipids have been demonstrated to be effective as transport vehicles for transporting biologically active substances such as small molecule drugs, polypeptides, proteins and nucleic acids into cells and/or intracellular compartments. These compositions generally comprise one or more "cationic" and/or amino (ionizable) lipids, including neutral lipids, structural lipids, and polymer conjugated lipids. Cationic and/or ionizable lipids include, for example, amine-containing lipids that can be readily protonated. While a variety of such lipid-containing nanoparticle compositions have been shown, safety, efficacy and specificity remain to be improved. Notably, the increased complexity of lipid nanoparticles (Lipid Nanoparticle, LNP) complicates their production and may increase their toxicity, a major concern that may limit their clinical use. For example, LNP siRNA particles (e.g., patsiran) require the prior use of steroids and antihistamines to eliminate unwanted immune responses (T. Coelho, D. Adams, A. Silva, et al, safety and efficacy of RNAi therapy for transthyretin amyloidosis, N Engl J Med, 369 (2013) 819-829.). Thus, there is a need to develop improved cationic lipid compounds, and compositions comprising the same, that facilitate the delivery of therapeutic and/or prophylactic agents, such as nucleic acids, to cells.
Disclosure of Invention
In one aspect, the present invention provides a novel cationic lipid compound which is a compound of formula (I)
Or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein
G 1 Is C 1~15 Alkylene or- (CH) 2 ) a C(O)O(CH 2 ) b -, wherein a and b are each an integer of 1 to 5;
G 2 is C 2~8 An alkylene group;
G 3 is C 1~4 An alkylene group;
R 1 is a hydrogen atom,C 6~14 Straight chain alkyl or- (CH) 2 ) c C(O)O(CH 2 ) d CH 3 Wherein c is an integer from 3 to 12 and d is an integer from 1 to 4;
R 2 is hydrogen atom, C 6~14 Linear or branched alkyl;
R 3 is unsubstituted, hydrogen atom, C 6~14 Linear or branched alkyl;
R 4 is unsubstituted, hydrogen atom, C 6~14 Linear or branched alkyl;
R 5 is C 6~25 Linear or branched alkyl;
X 1 and X 2 Respectively a methine group or an oxygen atom.
For example, the compound of formula (I) is one having the following structure:
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
。
a further aspect of the invention provides a composition comprising a carrier comprising a cationic lipid comprising a compound of formula (I) according to any one of the preceding claims or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof.
In a further aspect the present invention provides the use of a compound of formula (I) as defined above, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, or a composition as defined above, in the manufacture of a nucleic acid medicament, a genetic vaccine, a small molecule medicament, a polypeptide or a protein medicament.
In a further aspect the present invention provides the use of a compound of formula (I) as defined above, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, or a composition as defined above, in the manufacture of a medicament for the treatment of a disease or condition in a mammal in need thereof.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following brief description of the drawings of the embodiments will make it apparent that the drawings in the following description relate only to some embodiments of the present invention and are not limiting of the present invention.
FIG. 1 shows the results of cell transfection experiments for LNP formulations of eGFP-mRNA prepared based on YK-702, YK-705, YK-712, YK-716, SM-102 and Compound 1, wherein: a is YK-702, b is YK-705, c is YK-712, d is YK-716, e is SM-102, and f is Compound 1.
FIG. 2 shows the fluorescence absorbance intensities of LNP preparations of Fluc-mRNA prepared from different cationic lipids (YK-702, YK-705, YK-712, YK-716, YK-701, YK-703, YK-704, YK-706, YK-707, YK-708, YK-709, YK-710, YK-711, YK-713, YK-714, YK-715, SM-102, MC3, HHMA, DLin-K-C2-DMA, compound 1 and Lipofectamine 3000).
FIG. 3 shows cell viability of LNP preparations of Fluc-mRNA prepared from different cationic lipids (YK-702, YK-705, YK-712, YK-716, YK-701, YK-703, YK-704, YK-706, YK-707, YK-708, YK-709, YK-710, YK-711, YK-713, YK-714, YK-715, SM-102, MC3, HHMA, DLin-K-C2-DMA, compound 1 and Lipofectamine 3000) after addition to cell culture broth for 24 h.
FIG. 4 shows fluorescence images of mouse organs (heart, liver, spleen, lung, kidney) of LNP preparations of Fluc-mRNA prepared based on YK-704, YK-712, YK-716 and SM-102.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions of the embodiments of the present application will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present application. It will be apparent that the described embodiments are some, but not all, embodiments of the application. All other embodiments, which can be made by a person skilled in the art without creative efforts, based on the described embodiments of the present application fall within the protection scope of the present application.
The present application may be embodied in other specific forms without departing from its essential attributes. It is to be understood that any and all embodiments of the application may be combined with any other embodiment or features of multiple other embodiments to yield yet further embodiments without conflict. The application includes additional embodiments resulting from such combinations.
All publications and patents mentioned in this specification are herein incorporated by reference in their entirety. If a use or term used in any of the publications and patents incorporated by reference conflicts with a use or term used in the present application, the use or term of the present application controls.
The section headings used herein are for purposes of organizing articles only and should not be construed as limiting the subject matter.
Unless otherwise specified, all technical and scientific terms used herein have the ordinary meaning in the art to which the claimed subject matter belongs. In case there are multiple definitions for a term, the definitions herein control.
Except in the operating examples, or where otherwise indicated, all numbers expressing quantities of quantitative properties such as dosages set forth in the specification and claims are to be understood as being modified in all instances by the term "about". It should also be understood that any numerical range recited herein is intended to include all sub-ranges within that range and any combination of the individual endpoints of that range or sub-range.
As used in this application, the use of the terms "comprising," "including," or "containing," and the like, are intended to cover an element listed as a means that it is followed by such term and equivalents thereof, without excluding unrecited elements. The terms "comprising" or "including" as used herein, can be open, semi-closed, and closed. In other words, the term also includes "consisting essentially of …," or "consisting of ….
The term "pharmaceutically acceptable" in the present application means: the compound or composition is chemically and/or toxicologically compatible with the other ingredients comprising the formulation and/or with the human or mammal with which the disease or condition is to be prevented or treated.
The term "subject" or "patient" includes both humans and mammals in the present application.
The term "treatment" as used herein refers to the administration of one or more pharmaceutical substances to a patient or subject suffering from or having symptoms of a disease, to cure, alleviate, ameliorate or otherwise affect the disease or symptoms of the disease. In the context of the present application, the term "treatment" may also include prophylaxis, unless specifically stated to the contrary.
The term "solvate" in the present application refers to a complex formed by combining a compound of formula (I) or a pharmaceutically acceptable salt thereof and a solvent (e.g. ethanol or water). It will be appreciated that any solvate of the compound of formula (I) used in the treatment of a disease or condition, although potentially providing different properties (including pharmacokinetic properties), will result in the compound of formula (I) once absorbed into a subject, such that the use of the compound of formula (I) encompasses the use of any solvate of the compound of formula (I), respectively.
The term "hydrate" refers to the case where the solvent in the above term "solvate" is water.
It is further understood that the compound of formula (I) or a pharmaceutically acceptable salt thereof may be isolated in the form of a solvate, and thus any such solvate is included within the scope of the present invention. For example, the compound of formula (I) or a pharmaceutically acceptable salt thereof may exist in unsolvated forms as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
The term "pharmaceutically acceptable salt" refers to the relatively non-toxic, inorganic or organic acid addition salts of the compounds of the present invention. See, for example, s.m. Berge et al, "Pharmaceutical Salts",J. Pharm. Sci. 1977, 66, 1-19. Wherein the mineral acid is, for example, hydrochloric acid, hydrobromic acidHydroiodic acid, sulfuric acid, phosphoric acid or nitric acid, etc.; organic acids such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, caproic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2- (4-hydroxybenzoyl) -benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectate acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptonic acid, glycerophosphate, aspartic acid, sulfosalicylic acid, and the like. For example, HCl (or hydrochloric acid), HBr (or hydrobromic acid solution), methanesulfonic acid, sulfuric acid, tartaric acid, or fumaric acid may be used to form pharmaceutically acceptable salts with the compounds of formula (I).
The nitrogen-containing compounds of formula (I) of the present application may be converted to N-oxides by treatment with an oxidizing agent (e.g., m-chloroperoxybenzoic acid, hydrogen peroxide, ozone). Thus, the compounds claimed in the present application include not only nitrogen-containing compounds of the formula but also N-oxide derivatives thereof, under conditions of valence and structural permission.
Certain compounds of the application may exist in the form of one or more stereoisomers. Stereoisomers include geometric isomers, diastereomers and enantiomers. Thus, the presently claimed compounds also include racemic mixtures, single stereoisomers, and optically active mixtures. It will be appreciated by those skilled in the art that one stereoisomer may have better efficacy and/or lower side effects than the other stereoisomers. The single stereoisomers and the mixture with optical activity can be obtained by chiral source synthesis methods, chiral catalysis methods, chiral resolution methods and the like. The racemate can be chiral resolved by chromatographic resolution or chemical resolution. For example, separation can be performed by adding chiral acid resolving agents such as chiral tartaric acid and chiral malic acid to form salts with the compounds of the present application, and utilizing differences in physicochemical properties such as solubility of the products.
The application also includes all suitable isotopic variations of the compounds of the application. Isotopic variations are defined as compounds in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found or predominantly present in nature. Examples of isotopes that can be incorporated into compounds of the application include isotopes of hydrogen, carbon, nitrogen and oxygen, respectively, for example 2 H (deuterium), 3 H (tritium), 11 C、 13 C、 14 C、 15 N、 17 O and 18 O。
the term "alkyl" is meant to include both branched and straight chain saturated aliphatic monovalent hydrocarbon groups of the specified number of carbon atoms in the present application. The term "alkylene" is meant to include both branched and straight chain saturated aliphatic divalent hydrocarbon groups having the specified number of carbon atoms in the present application. C (C) n~m Is meant to include groups having a number of carbon atoms from n to m. For example C 2~5 Alkylene group includes C 2 Alkylene, C 3 Alkylene, C 4 Alkylene, C 5 An alkylene group.
The alkyl (or alkylene) group may be unsubstituted, or the alkyl (or alkylene) group may be substituted, wherein at least one hydrogen is replaced with another chemical group.
A "therapeutically effective amount" is an amount of a therapeutic agent that, when administered to a patient, ameliorates a disease or condition. A "prophylactically effective amount" is an amount of a prophylactic agent that, when administered to a subject, prevents a disease or condition. The amount of therapeutic agent constituting the "therapeutically effective amount" or the amount of prophylactic agent of the "prophylactically effective amount" varies with the therapeutic agent/prophylactic agent, the disease state and severity thereof, the age, weight, etc. of the patient/subject to be treated/prevented. One of ordinary skill in the art can routinely determine therapeutically effective and prophylactically effective amounts based on their knowledge and the present application.
In the present application, when the names of the compounds are not identical to the structural formulae, the structural formulae are determined.
It is to be understood that the term "compound of the application" as used herein may include, depending on the context: a compound of formula (I), an N-oxide thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, and mixtures thereof.
The term cationic lipid as used herein refers to a lipid that is positively charged at a selected pH.
Cationic liposomes readily bind to negatively charged nucleic acids, i.e., interact with negatively charged phosphate groups present in the nucleic acids by electrostatic forces, forming Lipid Nanoparticles (LNPs). LNP is one of the currently mainstream delivery vehicles.
The inventors found that, when screening a large number of compounds, it is very difficult to screen out suitable cationic lipid compounds that meet the following conditions: unlike the prior art, the cationic lipid has a typical cationic lipid structure, has extremely high transfection efficiency and extremely low cytotoxicity, and has high and sustained expression in mice. The inventors have found that certain compounds, such as YK-702, YK-705, YK-711, YK-716, and the like, can significantly improve intracellular transfection efficiency, significantly reduce cytotoxicity, significantly improve expression in the spleen of animals, and improve delivery efficiency compared to cationic lipids of which chemical structures are widely different or less different in the prior art.
Briefly, the present invention is based on at least the following findings:
the cationic lipid compounds of the present invention are useful for delivering nucleic acid molecules, small molecule compounds, polypeptides or proteins. Compared with the known cationic lipid compounds, the cationic lipid compounds of the invention have higher transfection efficiency and smaller cytotoxicity, remarkably improve the expression quantity of animal spleens, improve the delivery efficiency and have important clinical significance.
1. A series of cationic lipid compounds were designed, including YK-702, YK-705, YK-712 and YK-716, with tremendous differences in chemical structure compared to the prior art representative cationic lipids, such as SM-102, DLin-MC3-DMA (MC 3) and HHMA; there are structural similarities, for example DLin-K-C2-DMA and Compound 1.
SM-102 is a cationic lipid compound disclosed in WO20170409245A2 (page 29 of the specification) by morgana corporation (Moderna, inc.).
DLin-MC3-DMA (MC 3) is a cationic lipid compound disclosed in CN102625696B (page 6 of the specification) by the company Arilam pharmaceutical (Alnylam Pharmaceuticals, inc.).
HHMA is a cationic lipid compound disclosed in CN112979483B (page 7 of the specification) by Emblica Biotechnology, st.Job.
DLin-K-C2-DMA is a cationic lipid compound disclosed in CN102245590B (page 4 of the specification) by Tami drawing medicine Co.
Compound 1 is a cationic lipid compound disclosed in CN113039174a (page 4 of the specification) by intel-gerbera therapeutic stock.
Representative cationic lipids and structurally similar cationic lipids of the prior art have the following chemical structures:
(WO 2017049245A2, page 29);
(CN 102625696B, page 6 of the specification, compound of formula I);
(CN 112979483B, page 12 of the specification);
(CN 102245590B, page 4 of the specification);
(CN 113039174A, page 4 of the specification).
2. Of this series of compounds designed, LNP formulations prepared from YK-702, YK-705, YK-712 and YK-716 showed significantly improved cell transfection efficiency, significantly reduced cytotoxicity and significantly improved mRNA expression in mouse liver and spleen compared to the cationic lipids typical in the prior art (whether of widely structurally different cationic lipids such as SM-102, MC3 and HHMA, or of structurally similar cationic lipids such as DLin-K-C2-DMA and Compound 1). For example, cell transfection efficiency YK-716 can be up to 6.73 times that of SM-102, 70.91 times that of MC3, 10.10 times that of HHMA, 16.84 times that of DLin-K-C2-DMA, 9.54 times that of Compound 1, and 12.41 times that of Lipofectamine 3000; cell viability YK-705 was 8% higher than SM-102, 14% higher than MC3, 24% higher than HHMA, 21% higher than DLin-K-C2-DMA, 14% higher than Compound 1, 61% higher than Lipofectamine 3000; mRNA was expressed in liver and spleen of mice in 6.34-fold and 6.79-fold amounts of SM-102, YK-716, respectively.
3. In a series of compounds with small chemical structure difference, LNP preparations prepared from YK-702, YK-705, YK-712 and YK-716 have remarkably improved cell transfection efficiency, remarkably reduced cytotoxicity and remarkably improved mRNA expression level in mouse livers and spleens compared with other compounds. For example, YK-716 cells can be transfected with 418.45 times of YK-703 and 468.88 times of YK-715, cytotoxicity can be reduced by 43% compared with YK-701, and mRNA expression in liver and spleen of mice can be 242.76 times and 325.87 times of YK-704.
4. Through unique design and screening, the application discovers that certain compounds, such as YK-702, YK-705, YK-712 and YK-716, can be delivered with significantly improved cell transfection efficiency, significantly reduced cytotoxicity and significantly improved expression levels in the liver and spleen of animals, with improved delivery efficiency, and unexpected technical results over the cationic lipids typical of the prior art (whether of greatly structurally different cationic lipids such as SM-102, MC3 and HHMA, or of structurally similar cationic lipids such as DLin-K-C2-DMA and Compound 1).
In summary, the present application, through unique design and screening, has discovered compounds such as YK-702, YK-705, YK-712 and YK-716. These compounds have significantly improved cell transfection efficiency, significantly reduced cytotoxicity, and significantly improved expression in animal liver and spleen compared to the cationic lipids represented by the prior art, whether they are cationic lipids of greatly different structures such as SM-102, MC3 and HHMA, or similar structures such as DLin-K-C2-DMA and compound 1.
The method comprises the following steps:
1. the compounds contemplated by the present application, including YK-702, YK-705, YK-712 and YK-716, have chemical structures that differ significantly from the cationic lipids typical of the prior art, such as SM-102, MC3 and HHMA; there are minor differences, such as DLin-K-C2-DMA and Compound 1.
1) Compared with the typical cationic lipids SM-102, MC3 and HHMA in the prior art, the chemical structure of the compound designed by the application is completely different and has great difference. SM-102, MC3 and HHMA have no acetal structure, and the compounds designed by the application all have five-membered ring acetal structures.
2) The chemical structure of the compounds contemplated by the present application differs less than prior art cationic lipids comprising acetal structures, such as DLin-K-C2-DMA and compound 1. DLin-K-C2-DMA and the compound of the application all contain five-membered ring acetal structures, and other structures are slightly different; the acetal structure of the compound 1 is a common branched structure, but both the compound 1 and the compound designed by the application contain a hydroxyethyl tertiary amine structure.
2. The transfection efficiency of cells in vitro is obviously improved compared with that of the representative cationic lipid compounds in the prior art (whether the structural differences are large or the structures are similar).
1) Of the designed series of compounds, LNP preparations prepared from YK-702, YK-705, YK-712 and YK-716 have the highest cell transfection efficiency, and compared with the representative cationic lipids in the prior art, the LNP preparations have the advantages of greatly different structures (such as SM-102, MC3 and HHMA) or very small structure difference (such as DLin-K-C2-DMA and compound 1), and the cell transfection efficiency is remarkably improved. For example, YK-716 can be up to 6.73 times SM-102, 70.91 times MC3, 10.10 times HHMA, 16.84 times DLin-K-C2-DMA, 9.54 times Compound 1, and 12.41 times Lipofectamine 3000.
2) Will be of similar structure, X 1 =O、X 2 =CH、R 3 =no substituent, R 4 A series of compounds of the formula YK-701, YK-703, YK-704, YK-713, YK-714 and YK-715, which differ structurally only slightly from the individual groups compared to YK-702, YK-705 and YK-712, are shown. Cell transfection results show that the activity of the series of compounds is very different, and the cell transfection efficiency of YK-702, YK-705 and YK-712 is highest. The cell transfection efficiency of YK-702 can reach 19.89 times of YK-701, 225.35 times of YK-703, 157.50 times of YK-704, 103.88 times of YK-713, 119.84 times of YK-714 and 252.51 times of YK-715 respectively. The cell transfection efficiency of YK-705 can reach 23.29 times of YK-701, 263.81 times of YK-703, 184.38 times of YK-704, 121.61 times of YK-713, 140.29 times of YK-714 and 295.60 times of YK-715 respectively. The cell transfection efficiency of YK-712 can reach 33.93 times of YK-701, 384.32 times of YK-703, 268.60 times of YK-704, 177.16 times of YK-713, 204.37 times of YK-714 and 430.63 times of YK-715 respectively, and the transfection efficiency is obviously improved.
3) Similar to the structure, X 1 =O、X 2 =CH、R 2 =H、R 3 =no substituent, R 4 = C 8 Compared with YK-708, YK-709, YK-710 and YK-711, the transfection efficiency of YK-716 cells is obviously improved, and the transfection efficiency can reach 5.63 times, 11.97 times, 7.03 times and 44.48 times of YK-708, YK-709, YK-710 and YK-711 respectively.
4) Similar to the structure, X 1 =CH、X 2 =O、R 1 =C 8 Straight chain alkyl or- (CH) 2 ) 7 C(O)OCH 2 CH 3 、R 2 =H、R 3 =C 8 Straight chain alkyl, R 4 Compared with YK-706 and YK-707, the transfection efficiency of YK-716 cells is obviously improved, and the transfection efficiency can reach 8.04 times and 3.92 times of YK-706 and YK-707 respectively.
3. Cytotoxicity is significantly reduced compared to the typical cationic lipids of the prior art (whether of widely differing or similar structure).
1) The series of compounds contemplated by the present application, including YK-702, YK-705, YK-712 and YK-716, have chemical structures that differ significantly from the prior art cationic lipids, such as SM-102, MC3 and HHMA; there are structural similarities, for example DLin-K-C2-DMA and Compound 1. LNP formulations prepared from YK-705 and YK-716 were minimally cytotoxic and significantly improved in cell viability compared to the typical cationic lipid compounds of the prior art (whether of widely differing or similar structure). For example, YK-705 cell viability was 14% higher than MC3, 24% higher than HHMA, 21% higher than DLin-K-C2-DMA, 14% higher than Compound 1, 61% higher than Lipofectamine 3000. The cytotoxicity of LNP formulations prepared therefrom cannot be speculated on the basis of the structure of cationic lipid compounds, and there is a strong possibility that the cytotoxicity to transfected cells is very different, whether they are structurally different or structurally similar compounds.
2) Similar to the structure, X 1 =O、X 2 =CH、R 3 =no substituent, R 4 A series of compounds, e.g., YK-701, YK-702, YK-703, YK-704, YK-713, YK-714 and YK-715, =H, differing only slightly in their individual groups compared to YK-705, showed a very large difference in cytotoxicity, with YK-705 having the highest cell viability, 44% higher than YK-701, 10% higher than YK-702, 24% higher than YK-703, 11% higher than YK-704, 8% higher than YK-713 and 11% higher than YK-715, respectively, and significantly improved cell viability.
3) Similar to the structure, X 1 =O、X 2 =CH、R 2 =H、R 3 =no substituent, R 4 = C 8 Compared with YK-708, YK-709, YK-710 and YK-711, the linear alkyl compounds have significantly improved YK-716 cell survival rate, which can be 15% higher than YK-708, 8% higher than YK-709, 23% higher than YK-710 and 10% higher than YK-711, respectively.
4) Similar to the structure, X 1 =CH、X 2 =O、R 1 =C 8 Straight chain alkyl or- (CH) 2 ) 7 C(O)OCH 2 CH 3 、R 2 =H、R 3 =C 8 Straight chainAlkyl, R 4 Compared with YK-706 and YK-707, the transfection efficiency of YK-705 and YK-716 cells is obviously improved by 24% and 23% respectively higher than that of YK-706 and 31% and 30% higher than that of YK-707.
mRNA expression level in animal spleen is obviously raised compared with that of cationic lipid in available technology.
1) Compared with the representative cationic lipid in the prior art, the LNP preparation prepared by YK-712 and YK-716 has obviously improved expression level of mRNA in the liver and spleen of mice, especially in the spleen. For example, YK-712 and YK-716 can be expressed in spleen up to 6.52-fold and 6.79-fold, respectively, of SM-102. mRNA was consistent with the results of cell transfection in example 6 in terms of mouse liver and spleen expression.
2) LNP preparations prepared from YK-712 and YK-716 showed the highest expression intensity of mRNA in the liver and spleen of mice compared to the compound YK-704, which was similar in structure and slightly different in individual groups. For example, YK-712 can be expressed in liver and spleen in 237.23-fold and 312.86-fold, respectively, and YK-716 can be expressed in liver and spleen in 242.76-fold and 325.87-fold, respectively, of YK-704. mRNA was consistent with cell transfection activity in terms of expression in mice.
In one aspect, the present invention provides a novel cationic lipid compound for delivering a therapeutic or prophylactic agent. The cationic lipid compounds of the present invention are useful for delivering nucleic acid molecules, small molecule compounds, polypeptides or proteins. Compared with the known cationic lipid compounds, the cationic lipid compounds of the invention show higher transfection efficiency and lower cytotoxicity, and improve delivery efficiency and safety.
In one aspect, the present invention provides a novel cationic lipid compound which is a compound of formula (I)
Or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein:
G 1 is C 1~15 Alkylene or- (CH) 2 ) a C(O)O(CH 2 ) b -,Wherein a and b are each an integer of 1 to 5;
G 2 is C 2~8 An alkylene group;
G 3 Is C 1~4 An alkylene group;
R 1 is hydrogen atom, C 6~14 Straight chain alkyl or- (CH) 2 ) c C(O)O(CH 2 ) d CH 3 Wherein c is an integer from 3 to 12 and d is an integer from 1 to 4;
R 2 is hydrogen atom, C 6~14 Linear or branched alkyl;
R 3 is unsubstituted, hydrogen atom, C 6~14 Linear or branched alkyl;
R 4 is unsubstituted, hydrogen atom, C 6~14 Linear or branched alkyl;
R 5 is C 6~25 Linear or branched alkyl;
X 1 and X 2 Respectively a methine group or an oxygen atom.
In one embodiment, G 1 Is unsubstituted C 1~12 Alkylene groups, e.g. G 1 Is unsubstituted C 1 Alkylene, C 5 Alkylene, C 8 Alkylene, C 4 Alkylene or C 12 An alkylene group. In another embodiment, G 1 Is- (CH) 2 ) 3 C(O)OCH 2 -。
In one embodiment, G 2 Is C 3~7 Alkylene groups, e.g. G 2 Is C 5 Alkylene or C 7 An alkylene group.
In one embodiment, G 3 Is C 2~3 Alkylene groups, e.g. G 3 Is C 2 An alkylene group.
In one embodiment, R 1 Is C 5-13 Straight-chain alkyl radicals, e.g. R 1 Is C 10 、C 8 、C 7 、C 9 Or C 13 A linear alkyl group. In another embodiment, R 1 Is- (CH) 2 ) 11 C(O)OCH 2 CH 3 Or- (CH) 2 ) 7 C(O)OCH 2 CH 3 。
In one embodiment, R 2 Is a hydrogen atom. In another embodiment, R 2 Is C 10 、C 8 、C 7 Or C 9 A linear alkyl group.
In one embodiment, R 3 Is unsubstituted. In another embodiment, R 3 Is C 7~12 Straight-chain alkyl groups, e.g. R 3 Is C 8 A linear alkyl group.
In one embodiment, R 4 Is a hydrogen atom. In another embodiment, R 4 Is C 7~12 Straight-chain alkyl groups, e.g. R 4 Is C 8 A linear alkyl group. In another embodiment, R 4 Is unsubstituted.
In one embodiment, R 5 Is C 6~15 Straight-chain alkyl groups, e.g. R 5 Is C 11 Or C 10 A linear alkyl group. In another embodiment, R 5 Is C 10~22 Branched alkyl groups, e.g. R 5 Is C 17 Branched alkyl, in particular R 5 Is that。
In one embodiment, X 1 Is a methine group. In another embodiment, X 1 Is an oxygen atom.
In one embodiment, X 2 Is a methine group. In another embodiment, X 2 Is an oxygen atom.
In exemplary embodiments, the compound is selected from the following compounds or N-oxides, solvates, pharmaceutically acceptable salts or stereoisomers thereof:
table 1: comparison of chemical structures of cationic lipids designed according to the present invention
/>
In yet another aspect, the present invention provides a composition comprising a carrier comprising a cationic lipid comprising a compound of formula (I) as described above or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof.
In one embodiment, the composition is a nanoparticle formulation having an average size of 10nm to 300nm, preferably 90nm to 260nm; the nanoparticle formulation has a polydispersity of 50% or less, preferably 40% or less, more preferably 30% or less.
Cationic lipids
In one embodiment of the composition/carrier of the present invention, the cationic lipid is one or more selected from the compounds of formula (I) above or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof. In one embodiment, the cationic lipid is a compound of formula (I) selected from the group consisting of those described above. For example, the cationic lipid is a compound YK-702, YK-705, YK-712 or YK-716. In a preferred embodiment, the cationic lipid is compound YK-702, in a preferred embodiment, the cationic lipid is compound YK-705, in another preferred embodiment, the cationic lipid is compound YK-712, and in another preferred embodiment, the cationic lipid is compound YK-716.
In another embodiment of the composition/carrier of the present invention, the cationic lipid comprises: (a) One or more selected from the compounds of formula (I) above or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof; (b) One or more other ionizable lipid compounds different from (a). (b) The cationic lipid compound may be a commercially available cationic lipid, or a cationic lipid compound reported in the literature. For example, (B) the cationic lipid compound may be SM-102 in CN102625696B, DLin-K-C2-DMA in CN102245590B, or compound 1 in CN 113039174A.
In one embodiment, the cationic lipid comprises 25% -75% of the carrier by mole, for example 30%, 40%, 50%, 55%, 60%, 65%, 70%.
The carrier may be used to deliver an active ingredient such as a therapeutic or prophylactic agent. The active ingredient may be enclosed within a carrier or may be combined with a carrier.
For example, the therapeutic or prophylactic agent includes one or more of a nucleic acid molecule, a small molecule compound, a polypeptide, or a protein. Such nucleic acids include, but are not limited to, single-stranded DNA, double-stranded DNA, and RNA. Suitable RNAs include, but are not limited to, small interfering RNAs (sirnas), asymmetric interfering RNAs (airnas), micrornas (mirnas), dicer-substrate RNAs (dsRNA), small hairpin RNAs (shrnas), messenger RNAs (mrnas), and mixtures thereof.
Neutral lipids
The carrier may comprise neutral lipids. Neutral lipids in the context of the present invention are lipids that are non-charged at a selected pH or that act as a helper in zwitterionic form. The neutral lipids may modulate nanoparticle mobility into lipid bilayer structures and increase efficiency by promoting lipid phase changes, while also potentially affecting target organ specificity.
In one embodiment, the molar ratio of the cationic lipid to the neutral lipid is about 1:1 to 15:1, such as about 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, and 2:1. In a preferred embodiment, the molar ratio of the cationic lipid to the neutral lipid is about 4:1.
For example, the neutral lipids may include one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramides, sterols, and derivatives thereof.
The carrier component of the cationic lipid-containing composition may comprise one or more neutral lipid-phospholipids, such as one or more (poly) unsaturated lipids. Phospholipids may assemble into one or more lipid bilayers. In general, phospholipids may include a phospholipid moiety and one or more fatty acid moieties.
The neutral lipid moiety may be selected from the non-limiting group consisting of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin. The fatty acid moiety may be selected from the non-limiting group consisting of: lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanic acid, arachic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid and docosahexaenoic acid. Non-natural species including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes are also contemplated. For example, the phospholipid may be functionalized with or crosslinked with one or more alkynes (e.g., alkenyl groups with one or more double bonds replaced with triple bonds). Under appropriate reaction conditions, alkynyl groups may undergo copper-catalyzed cycloaddition reactions upon exposure to azide. These reactions can be used to functionalize the lipid bilayer of the composition to facilitate membrane permeation or cell recognition, or to couple the composition with a useful component such as a targeting or imaging moiety (e.g., dye).
Neutral lipids useful in these compositions may be selected from the non-limiting group consisting of: 1, 2-Dioleoyl-sn-glycero-3-phosphorylcholine (DLPC), 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine (DMPC), 1, 2-dioleoyl-sn-glycero-3-phosphorylcholine (DOPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphorylcholine (DPPC), 1, 2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC), 1, 2-dioleoyl-sn-glycero-phosphorylcholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine (POPC), 1, 2-dioleoyl-octadecenyl-sn-glycero-3-phosphorylcholine (18:0 DietherPC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-3-phosphorylcholine (OChems PC), 1-hexadecyl-sn-3-phosphorylcholine (C16), 1, 2-dioleoyl-sn-glycero-3-phosphorylcholine, 1-dioleoyl-2-dioleoyl-glycero-3-phosphorylcholine (POPC), 1, 2-dioleoyl-sn-glycero-3-phosphate ethanolamine (DOPE), 1, 2-di-phytanoyl-sn-glycero-3-phosphate ethanolamine (ME 16.0 PE), 1, 2-di-stearoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-oleoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-linolenoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-arachidonoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-docosahexaenoic acyl-sn-glycero-3-phosphate ethanolamine, 1, 2-dioleoyl-sn-glycero-3-phosphate sodium salt (DOPG), 1, 2-di-oleoyl-rac-3-phosphate sodium salt (DOPG) dipalmitoyl phosphatidylglycerol (DPPG), palmitoyl phosphatidylethanolamine (POPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylethanolamine (DMPE), 1-stearoyl-2-oleoyl-stearoyl ethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyl-based phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE) and mixtures thereof.
In some embodiments, the neutral lipid comprises DSPC. In certain embodiments, the neutral lipid comprises DOPE. In some embodiments, the neutral lipid comprises both DSPC and DOPE.
Structured lipids
The carrier of the composition comprising the cationic lipid may also comprise one or more structural lipids. Structured lipids in the present invention refer to lipids that enhance the stability of the nanoparticle by filling the interstices between the lipids.
In one embodiment, the molar ratio of the cationic lipid to the structural lipid is about 1:1-5:1, e.g., about 1.0:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1, 2.0:1.
The structural lipid may be selected from, but is not limited to, the group consisting of: cholesterol, non-sterols, sitosterols, ergosterols, campesterols, stigmasterols, brassicasterol, lycorine, ursolic acid, alpha-tocopherols, corticosteroids, and mixtures thereof. In some embodiments, the structural lipid is cholesterol. In some embodiments, the structural lipids include cholesterol and corticosteroids (such as prednisolone, dexamethasone, prednisone, and hydrocortisone) or combinations thereof.
Polymer conjugated lipids
The carrier of the composition comprising the cationic lipid may also comprise one or more polymer conjugated lipids. The polymer conjugated lipid mainly refers to polyethylene glycol (PEG) modified lipid. Hydrophilic PEG stabilizes LNP, regulates nanoparticle size by limiting lipid fusion, and increases nanoparticle half-life by reducing non-specific interactions with macrophages.
In one embodiment, the polymer conjugated lipid is selected from one or more of the following: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol. The PEG modified PEG molecular weight is typically 350-5000Da.
For example, the polymer conjugated lipid is selected from one or more of the following: distearoyl phosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG 2000), dimyristoylglycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG 2000) and methoxypolyethylene glycol ditetradecylamide (ALC-0159).
In one embodiment of the composition/carrier of the present invention, the polymer conjugated lipid is DMG-PEG2000.
In one embodiment of the composition/carrier of the present invention, the carrier comprises neutral lipid, structural lipid and polymer conjugated lipid, and the molar ratio of the cationic lipid, the neutral lipid, the structural lipid and the polymer conjugated lipid is (25-75): (5-25): (15-65): (0.5-10), for example (30-49): (7.5-15): (35-55): (1-5).
In one embodiment of the composition/carrier of the invention, the carrier comprises neutral lipids, structural lipids and polymer conjugated lipids, the molar ratio of the cationic lipids, the neutral lipids, the structural lipids and the polymer conjugated lipids being 40:10:48.5:1.5 or 49:10:39.5:1.5.
Therapeutic and/or prophylactic agent
The composition may include one or more therapeutic and/or prophylactic agents. In one embodiment, the mass ratio of carrier to the therapeutic or prophylactic agent is 10:1 to 30:1, e.g., 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1.
In one embodiment, the mass ratio of carrier to the therapeutic or prophylactic agent is 12.5:1 to 20:1, preferably 15:1.
The therapeutic or prophylactic agent includes, but is not limited to, one or more of a nucleic acid molecule, a small molecule compound, a polypeptide, or a protein.
For example, the therapeutic or prophylactic agent is a vaccine or compound capable of eliciting an immune response.
The vectors of the present invention can deliver therapeutic and/or prophylactic agents to mammalian cells or organs, and thus the present invention also provides methods of treating a disease or disorder in a mammal in need thereof, comprising administering to the mammal a composition comprising a therapeutic and/or prophylactic agent and/or contacting mammalian cells with the composition.
Therapeutic and/or prophylactic agents include bioactive substances and are alternatively referred to as "active agents". The therapeutic and/or prophylactic agent can be a substance that, upon delivery to a cell or organ, causes a desired change in the cell or organ or other body tissue or system. Such species may be used to treat one or more diseases, disorders or conditions. In some embodiments, the therapeutic and/or prophylactic agent is a small molecule drug that can be used to treat a particular disease, disorder, or condition. Examples of drugs that may be used in the composition include, but are not limited to, antineoplastic agents (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate and streptozotocin), antineoplastic agents (e.g., dactinomycin D (actinomycin D), vincristine, vinblastine, cytosine arabinoside cytosine arabinoside, anthracycline (anthracycline), alkylating agents, platinum compounds, antimetabolites and nucleoside analogs such as methotrexate and purine and pyrimidine analogs, anti-infective agents, local anesthetics (e.g., dibucaine) and chlorpromazine, beta-adrenergic blockers (e.g., streptozotocin), anti-inflammatory agents (e.g., benzodiazepinephrine), and anti-inflammatory agents (e.g., benzodiazepinephrine), antimuscarin (e.g., benzodiazepinephrine), and antimuscarin (e.g., benzodiazepinephrine), antimuscarin (e.g., benzodiazepinephrine (e), and antimuscarin (e.g., benzodiazepinephrine (e), and other drugs (e.g., benzodiazepinephrine), and other drugs (e.g., benzoglibin), which may be used in combination, ciprofloxacin (ciprofloxacin) and cefoxitin), antifungal agents (e.g., miconazole, terconazole, econazole, isoconazole, butoconazole, clotrimazole, itraconazole, nystatin, naftifine, and amphotericin B (amphotericin B)), antiparasitic agents, hormones, hormone antagonists, immunomodulators, neurotransmitters, antagonists, antiglaucomas, vitamins, sedatives, and imaging agents.
In some embodiments, the therapeutic and/or prophylactic agent is a cytotoxin, a radioactive ion, a chemotherapeutic agent, a vaccine, a compound that elicits an immune response, and/or another therapeutic and/or prophylactic agent. Cytotoxins or cytotoxic agents include any agent that is detrimental to cells. Examples include, but are not limited to, taxol (taxol), cytochalasin B (cytochalasin B), gramicidin D (gramicidin D), ethidium bromide (ethidium bromide), emetine (emetine), mitomycin (mitomycin), etoposide (etoposide), teniposide (teniposide), vincristine, vinblastine, colchicine (colchicine), doxorubicin, daunorubicin (daunorubicin), dihydroxyanthracenedione (dihydroxy anthracin dione), mitoxantrone, mithramycin (mithramycin), actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine (procaine), tetracaine (tetracaine), lidocaine (lidocaine), propranolol, puromycin, maytansinoids (maytansinoid) such as maytansinol (maytansine), lanmycin (rachimycin) (CC-1065), and analogs or homologs thereof. Radioions include, but are not limited to, iodine (e.g., iodine 125 or iodine 131), strontium 89, phosphorus, palladium, cesium, iridium, phosphate, cobalt, yttrium 90, samarium 153, and praseodymium. Vaccines include compounds and formulations capable of providing immunity against one or more conditions associated with infectious diseases such as influenza, measles, human Papilloma Virus (HPV), rabies, meningitis, pertussis, tetanus, plague, hepatitis and tuberculosis and may include mRNA encoding antigens and/or epitopes that are the source of infectious diseases. Vaccines can also include compounds and formulations that direct immune responses against cancer cells and can include mRNA encoding tumor cell-derived antigens, epitopes, and/or neoepitopes. Compounds that elicit an immune response may include vaccines, corticosteroids (e.g., dexamethasone), and other species. In some embodiments, a vaccine and/or compound capable of eliciting an immune response is administered intramuscularly through a composition comprising a compound according to formula (I), (IA), (IB), (II), (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg) or (III) (e.g., compound 3, 18, 20, 25, 26, 29, 30, 60, 108-112 or 122). Other therapeutic and/or prophylactic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, and 5-fluorouracil dacarbazine), alkylating agents (e.g., nitrogen mustard (mechlorethamine), thiotepa (thiopa), chlorambucil (chloranserine), azithromycin (CC-1065), melphalan (melphalan), carmustine (carmustine, BSNU), robustin (lomustine, CCNU), cyclophosphamide, busulfan (busulfan), dibromomannitol, streptozotocin, mitomycin C, and cisplatin (II) (DDP), cisplatin), anthracyclines (e.g., daunomycin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly dactinomycin), dactinomycin (formenin), and vincristine (AMC), and antimuscarines (e.g., mitomycin, and the like).
In other embodiments, the therapeutic and/or prophylactic agent is a protein. Therapeutic proteins that may be used in the nanoparticles of the present invention include, but are not limited to, gentamicin, amikacin, insulin, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), factor VIR, luteinizing Hormone Releasing Hormone (LHRH) analogs, interferons, heparin, hepatitis B surface antigen, typhoid vaccines, and cholera vaccines.
In some embodiments, the therapeutic agent is a polynucleotide or nucleic acid (e.g., ribonucleic acid or deoxyribonucleic acid). The term "polynucleotide" is intended to include in its broadest sense any compound and/or substance that is or can be incorporated into an oligonucleotide chain. Exemplary polynucleotides for use in accordance with the present invention include, but are not limited to, one or more of the following: deoxyribonucleic acid (DNA); ribonucleic acids (RNAs), including messenger mrnas (mrnas), hybrids thereof; RNAi-inducing factors; RNAi factor; siRNA; shRNA; a miRNA; antisense RNA; ribozymes; catalytic DNA; RNA that induces triple helix formation; an aptamer, and the like. In some embodiments, the therapeutic and/or prophylactic agent is RNA. The RNAs useful in the compositions and methods described herein may be selected from the group consisting of, but not limited to: shortmer, antagomir antisense RNA, ribozyme, small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA), and mixtures thereof. In certain embodiments, the RNA is mRNA.
In certain embodiments, the therapeutic and/or prophylactic agent is mRNA. The mRNA may encode any polypeptide of interest, including any naturally or non-naturally occurring or otherwise modified polypeptide. The polypeptide encoded by the mRNA may be of any size and may have any secondary structure or activity. In some embodiments, the polypeptide encoded by the mRNA may have a therapeutic effect when expressed in a cell.
In other embodiments, the therapeutic and/or prophylactic agent is an siRNA. siRNA is capable of selectively reducing expression of a gene of interest or down-regulating expression of the gene. For example, the siRNA can be selected such that a gene associated with a particular disease, disorder, or condition is silenced after administration of a composition comprising the siRNA to a subject in need thereof. The siRNA may comprise a sequence complementary to an mRNA sequence encoding a gene or protein of interest. In some embodiments, the siRNA may be an immunomodulatory siRNA.
In certain embodiments, the therapeutic and/or prophylactic agent is sgRNA and/or cas9 mRNA. sgRNA and/or cas9 mRNA may be used as a gene editing tool. For example, the sgRNA-cas9 complex can affect mRNA translation of cellular genes.
In some embodiments, the therapeutic and/or prophylactic agent is an shRNA or a vector or plasmid encoding the same. shRNA may be produced inside the target cell after delivery of the appropriate construct into the nucleus. Constructs and mechanisms related to shRNA are well known in the relevant arts.
Diseases or conditions
The compositions/carriers of the invention can deliver therapeutic or prophylactic agents to a subject or patient. The therapeutic or prophylactic agent includes, but is not limited to, one or more of a nucleic acid molecule, a small molecule compound, a polypeptide, or a protein. Thus, the composition of the invention can be used for preparing nucleic acid medicaments, gene vaccines, small molecule medicaments, polypeptides or protein medicaments. Because of the wide variety of therapeutic or prophylactic agents described above, the compositions of the present invention are useful in the treatment or prevention of a variety of diseases or conditions.
In one embodiment, the disease or disorder is characterized by dysfunctional or abnormal protein or polypeptide activity.
For example, the disease or disorder is selected from the group consisting of: infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases and metabolic diseases.
In one embodiment, the infectious disease is selected from the group consisting of a disease caused by coronavirus, influenza virus, or HIV virus, pediatric pneumonia, rift valley fever, yellow fever, rabies, or multiple herpes.
Other components
The composition may include one or more components other than those described in the preceding section. For example, the composition may include one or more hydrophobic small molecules, such as vitamins (e.g., vitamin a or vitamin E) or sterols.
The composition may also include one or more permeability enhancing molecules, carbohydrates, polymers, surface modifying agents, or other components. The permeability enhancing molecule may be, for example, a molecule described in U.S. patent application publication No. 2005/0222064. Carbohydrates may include simple sugars (e.g., glucose) and polysaccharides (e.g., glycogen, and derivatives and analogs thereof).
Surface modifying agents may include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyl dioctadecyl ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrins), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamers), mucolytics (e.g., acetylcysteine, mugwort, bromelain, papain, dyers woad), bromohexine, carbocistein, eplerenone, mesna, ambroxol, sobrinol, domidol, ritodtein, stenine, tiopronin, gelsin, thymosin beta 4, dnase alpha, neogenin, and dnase, such as dnase. The surface modifying agent may be disposed within and/or on the nanoparticle of the composition (e.g., by coating, adsorption, covalent attachment, or other means).
The composition may further comprise one or more functionalized lipids. For example, the lipid may be functionalized with an alkynyl group that may undergo a cycloaddition reaction when exposed to an azide under appropriate reaction conditions. In particular, lipid bilayers can be functionalized in this manner with one or more groups effective to facilitate membrane permeation, cell recognition, or imaging. The surface of the composition may also be conjugated to one or more useful antibodies. Functional groups and conjugates useful for targeted cell delivery, imaging, and membrane permeation are well known in the art.
In addition to these components, the composition may include any substance useful in pharmaceutical compositions. For example, the composition may include one or more pharmaceutically acceptable excipients or auxiliary ingredients such as, but not limited to, one or more solvents, dispersion media, diluents, dispersing aids, suspending aids, granulating aids, disintegrants, fillers, glidants, liquid vehicles, binders, surfactants, isotonic agents, thickening or emulsifying agents, buffers, lubricants, oils, preservatives, flavoring agents, coloring agents, and the like. Excipients such as starch, lactose or dextrin. Pharmaceutically acceptable excipients are well known in the art (see, e.g., remington's The Science and Practice of Pharmacy, 21 st edition, a.r. gennaro; lippincott, williams & Wilkins, baltimore, MD, 2006).
Examples of diluents may include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dibasic calcium phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and/or combinations thereof.
In some embodiments, compositions comprising one or more lipids described herein may also comprise one or more adjuvants, such as Glucopyranosyl Lipid Adjuvants (GLA), cpG oligodeoxyribonucleotides (e.g., class a or class B), poly (I: C), aluminum hydroxide, and Pam3CSK4.
The compositions of the present invention may be formulated in solid, semi-solid, liquid or gaseous form as, for example, tablets, capsules, ointments, elixirs, syrups, solutions, emulsions, suspensions, injections, aerosols. The compositions of the present invention may be prepared by methods well known in the pharmaceutical arts. For example, sterile injectable solutions can be prepared by incorporating the therapeutic or prophylactic agent in the required amount with various of the other ingredients described above in the appropriate solvent such as sterile distilled water and then filter-sterilizing. Surfactants may also be added to promote the formation of a uniform solution or suspension.
For example, the compositions of the present invention may be administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation. In one embodiment, the composition is administered subcutaneously.
The compositions of the present invention are administered in therapeutically effective amounts, which may vary not only with the particular agent selected, but also with the route of administration, the nature of the disease being treated and the age and condition of the patient, and may ultimately be at the discretion of the attendant physician or clinician. For example, a dose of about 0.001mg/kg to about 10mg/kg of the therapeutic or prophylactic agent may be administered to a mammal (e.g., a human).
The present invention includes, but is not limited to, the following embodiments:
1. a compound of formula (I)
Or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein
G 1 Is C 1~15 Alkylene or- (CH) 2 ) a C(O)O(CH 2 ) b -, wherein a and b are each an integer of 1 to 5;
G 2 is C 2~8 An alkylene group;
G 3 is C 1~4 An alkylene group;
R 1 is hydrogen atom, C 6~14 Straight chain alkyl or- (CH) 2 ) c C(O)O(CH 2 ) d CH 3 Wherein c is an integer from 3 to 12 and d is an integer from 1 to 4;
R 2 is hydrogen atom, C 6~14 Linear or branched alkyl;
R 3 is unsubstituted, hydrogen atom, C 6~14 Linear or branched alkyl;
R 4 is unsubstituted, hydrogen atom, C 6~14 Linear or branched alkyl;
R 5 is C 6~25 Linear or branched alkyl;
X 1 and X 2 Respectively a methine group or an oxygen atom.
2. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 1, wherein G 1 Is unsubstituted C 1~12 An alkylene group.
3. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 1 or 2, wherein G 1 Is unsubstituted C 1 Alkylene, C 5 Alkylene, C 8 Alkylene, C 4 Alkylene or C 12 An alkylene group.
4. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 1, wherein G 1 Is- (CH) 2 ) 3 C(O)OCH 2 -。
5. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein G 2 Is C 3~7 An alkylene group.
6. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 5, wherein G 2 Is C 5 Alkylene or C 7 An alkylene group.
7. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 5, wherein G 3 Is C 2~3 An alkylene group.
8. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 7, wherein G 3 Is C 2 An alkylene group.
9. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein R 1 Is C 5-13 A linear alkyl group.
10. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 9, wherein R 1 Is C 10 、C 8 、C 7 、C 9 Or C 13 A linear alkyl group.
11. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of embodiments 1-8, wherein R 1 Is- (CH) 2 ) 11 C(O)OCH 2 CH 3 Or- (CH) 2 ) 7 C(O)OCH 2 CH 3 。
12. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein R 2 Is a hydrogen atom.
13. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of embodiments 1-11, wherein R 2 Is C 10 、C 8 、C 7 Or C 9 A linear alkyl group.
14. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein R 3 Is unsubstituted.
15. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of embodiments 1-13, wherein R 3 Is C 7~12 A linear alkyl group.
16. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 15, wherein R 3 Is C 8 A linear alkyl group.
17. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein R 4 Is a hydrogen atom.
18. The compound of formula (I) according to any one of embodiments 1-16An N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 Is C 7~12 A linear alkyl group.
19. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 18, wherein R 4 Is C 8 A linear alkyl group.
20. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of embodiments 1-16, wherein R 4 Is unsubstituted.
21. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein R 5 Is C 6~15 A linear alkyl group.
22. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 21, wherein R 5 Is C 11 Or C 10 A linear alkyl group.
23. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of embodiments 1-20, wherein R 5 Is C 10~22 Branched alkyl groups.
24. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 23, wherein R 5 Is C 17 Branched alkyl groups.
25. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 24, wherein R 5 Is that。
26. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein X 1 Is a methine group.
27. According to the embodimentThe compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof as described in scheme 14, wherein X 1 Is an oxygen atom.
28. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to any one of the preceding embodiments, wherein X 2 Is a methine group.
29. The compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to embodiment 20, wherein X 2 Is an oxygen atom.
30. A compound of formula (I) according to embodiment 1 or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) has one of the following structures:
,
,
,
,
,
,/>
,
,
,
,
,/>
,
,
,
,
。
31. a compound of formula (I) according to embodiment 1 or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) is compound YK-702 having the structure:
。
32. a compound of formula (I) according to embodiment 1 or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) is compound YK-705 having the structure:
。
33. a compound of formula (I) according to embodiment 1 or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) is compound YK-712 having the structure:
。
34. a compound of formula (I) according to embodiment 1 or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) is a compound YK-716 having the structure:
。
35. A composition comprising a carrier comprising a cationic lipid comprising a compound of formula (I) according to any one of the preceding embodiments or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof.
36. The composition of embodiment 35, wherein the cationic lipid comprises 25% -75% of the carrier by mole.
37. The composition of any one of embodiments 35-36, wherein the carrier further comprises a neutral lipid.
38. The composition of embodiment 37, wherein the molar ratio of the cationic lipid to the neutral lipid is 1:1-15:1, preferably 4.5:1.
39. The composition of embodiment 37, wherein the neutral lipid comprises one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramides, sterols, and derivatives thereof.
40. The composition of embodiment 39, wherein the neutral lipid is selected from one or more of the following: 1, 2-Dioleoyl-sn-glycero-3-phosphorylcholine (DLPC), 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine (DMPC), 1, 2-dioleoyl-sn-glycero-3-phosphorylcholine (DOPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphorylcholine (DPPC), 1, 2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC), 1, 2-dioleoyl-sn-glycero-phosphorylcholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine (POPC), 1, 2-dioleoyl-octadecenyl-sn-glycero-3-phosphorylcholine (18:0 DietherPC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-3-phosphorylcholine (OChems PC), 1-hexadecyl-sn-3-phosphorylcholine (C16), 1, 2-dioleoyl-sn-glycero-3-phosphorylcholine, 1-dioleoyl-2-dioleoyl-glycero-3-phosphorylcholine (POPC), 1, 2-dioleoyl-sn-glycero-3-phosphate ethanolamine (DOPE), 1, 2-di-phytanoyl-sn-glycero-3-phosphate ethanolamine (ME 16.0 PE), 1, 2-di-stearoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-oleoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-linolenoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-arachidonoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-docosahexaenoic acyl-sn-glycero-3-phosphate ethanolamine, 1, 2-dioleoyl-sn-glycero-3-phosphate sodium salt (DOPG), 1, 2-di-oleoyl-rac-3-phosphate sodium salt (DOPG) dipalmitoyl phosphatidylglycerol (DPPG), palmitoyl phosphatidylethanolamine (POPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylethanolamine (DMPE), 1-stearoyl-2-oleoyl-stearoyl ethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyl-based phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE) and mixtures thereof.
41. The composition of embodiment 40, wherein the neutral lipid is DOPE and/or DSPC.
42. The composition of any one of embodiments 35-41, wherein the carrier further comprises a structural lipid.
43. The composition of embodiment 42, wherein the molar ratio of the cationic lipid to the structural lipid is 0.6:1-3:1.
44. The composition of any of embodiments 42-43, wherein the structural lipid is selected from one or more of the following: cholesterol, non-sterols, sitosterols, ergosterols, campesterols, stigmasterols, brassicasterol, lycorine, ursolic acid, alpha-tocopherol, corticosteroids.
45. The composition of embodiment 44, wherein the structural lipid is cholesterol.
46. The composition of any of embodiments 35-45, wherein the carrier further comprises a polymer conjugated lipid.
47. The composition of embodiment 46, wherein the molar ratio of the polymer conjugated lipid to the carrier is 0.5% -10%, preferably 1.5%.
48. The composition of any of embodiments 46-47, wherein the polymer conjugated lipid is selected from one or more of the following: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol.
49. The composition of embodiment 48, wherein the polymer conjugated lipid is selected from one or more of the following: distearoyl phosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG 2000), dimyristoylglycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG 2000) and methoxypolyethylene glycol ditetradecylamide (ALC-0159).
50. The composition of any of embodiments 35-49, wherein the carrier comprises neutral lipids, structural lipids, and polymer conjugated lipids in a molar ratio of (25-75): 5-25): 15-65): 0.5-10.
51. The composition of embodiment 50, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer conjugated lipid is (35-49): 7.5-15): 35-55): 1-5.
52. The composition of embodiment 51, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer conjugated lipid is 45:10:43.5:1.5.
53. The composition of any of embodiments 35-52, wherein the composition is a nanoparticle formulation having an average particle size of 10nm to 300nm; the polydispersity of the nanoparticle preparation is less than or equal to 50 percent.
54. The composition of embodiment 53, wherein the composition is a nanoparticle formulation having an average particle size of 90nm to 280nm; the polydispersity of the nanoparticle preparation is less than or equal to 45 percent.
55. The composition of any of embodiments 35-54, wherein the cationic lipid further comprises one or more other ionizable lipid compounds.
56. The composition of any of embodiments 35-55, further comprising a therapeutic or prophylactic agent.
57. The composition of embodiment 56, wherein the mass ratio of the carrier to the therapeutic or prophylactic agent is 10:1-30:1.
58. The composition of embodiment 57, wherein the mass ratio of the carrier to the therapeutic or prophylactic agent is 12.5:1-20:1.
59. The composition of embodiment 58, wherein the mass ratio of the carrier to the therapeutic or prophylactic agent is 15:1.
60. The composition of any of embodiments 56-59, wherein the therapeutic or prophylactic agent comprises one or more of a nucleic acid molecule, a small molecule compound, a polypeptide, or a protein.
61. The composition of any of embodiments 56-59, wherein the therapeutic or prophylactic agent is a vaccine or compound capable of eliciting an immune response.
62. The composition of embodiment 60, wherein the therapeutic or prophylactic agent is a nucleic acid.
63. The composition of embodiment 62, wherein the therapeutic or prophylactic agent is ribonucleic acid (RNA).
64. The composition of embodiment 62, wherein the therapeutic or prophylactic agent is deoxyribonucleic acid (DNA).
65. The composition of embodiment 63, wherein the RNA is selected from the group consisting of: small interfering RNAs (siRNA), asymmetric interfering RNAs (aiRNA), micrornas (miRNA), dicer-substrate RNAs (dsRNA), small hairpin RNAs (shRNA), messenger RNAs (mRNA), and mixtures thereof.
66. The composition of embodiment 65, wherein the RNA is mRNA.
67. The composition according to any one of the preceding embodiments, wherein the composition further comprises one or more pharmaceutically acceptable excipients.
68. Use of a compound of formula (I) according to any one of embodiments 1-34 or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, or a composition according to any one of embodiments 35-67, for the preparation of a nucleic acid drug, a genetic vaccine, a small molecule drug, a polypeptide or a protein drug.
69. Use of a compound of general formula (I) as described in any one of embodiments 1-34 or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, or a composition as described in any one of embodiments 35-67, in the manufacture of a medicament for treating a disease or disorder in a mammal in need thereof.
70. The use of embodiment 69, wherein the disease or disorder is characterized by dysfunctional or abnormal protein or polypeptide activity.
71. The use of embodiment 69, wherein the disease or disorder is selected from the group consisting of: infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases and metabolic diseases.
72. The use according to embodiment 71, wherein the infectious disease is selected from the group consisting of: diseases caused by coronavirus, influenza virus or HIV virus, pediatric pneumonia, rift valley fever, yellow fever, rabies, or various herpes.
73. The use according to any one of embodiments 69-72, wherein the mammal is a human.
74. The use according to any one of embodiments 69-73, wherein the medicament is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.
75. The use of embodiment 74, wherein the composition is administered subcutaneously.
76. The use of any one of embodiments 69-75 wherein a dose of about 0.001mg/kg to about 10mg/kg of the medicament is administered to the mammal.
Examples
The invention is further described below with reference to examples. The present invention is not limited to the following examples. The implementation conditions adopted in the embodiments can be further adjusted according to different requirements of specific use, and the implementation conditions which are not noted are conventional conditions in the industry. In the specific examples of the present invention, all the raw materials used are commercially available. Unless otherwise indicated, percentages are by weight in the context, and all temperatures are given in degrees celsius. The technical features of the various embodiments of the present invention may be combined with each other as long as they do not collide with each other.
The following abbreviations represent the following reagents, respectively:
DCM: dichloromethane; EDCI:1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride; DMAP: 4-dimethylaminopyridine; DCC: n, N' -dicyclohexylcarbodiimide; EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride; and rt: room temperature
Example 1: synthesis of cationic lipid compounds
1.6 Synthesis of undecyl- ((5- (2, 2-diheptyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) hexanoate (YK-701)
The synthetic route is as follows:
step one: synthesis of 2- (5-bromopentyl) oxirane (YK-701-PM 1)
7-Bromoheptene (3.0 g, 16.9 mmol) was dissolved in dichloromethane (20 mL) and added portionwise with icemCPBA (4.1 g, 23.7 mmol), the ice bath was removed after the addition was complete. The reaction was stirred at room temperature for 20 hours, washed with saturated aqueous sodium hydrogencarbonate (10 mL. Times.3), dried over anhydrous sodium sulfate, and filtered. The solvent was removed by spin-drying under reduced pressure to give YK-701-PM1 (3.17 g,16.4mmol, 97.0%).
Step two: synthesis of 7-bromoheptane-1, 2-diol (YK-701-PM 2)
YK-701-PM1 (3.17 g,16.4 mmol) was dissolved in a mixed solution of DMF (30 mL) and water (30 mL), trifluoroacetic acid (4.1 g,36.1 mmol) was slowly added under ice bath, and after removal of the ice bath, the reaction was carried out at room temperature for 8 hours. After the reaction was completed, the mixture was extracted with ethyl acetate (15 mL. Times.2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-50% ethyl acetate/n-hexane) to give YK-701-PM2 (650 mg, 3.1mmol, 19.0%).
Step three: synthesis of undecyl 6- ((6, 7-dihydroxyheptyl) (2-hydroxyethyl) amino) hexanoate (YK-701-PM 3)
YK-701-PM2 (154 mg, 0.73 mmol) and undecyl 6- ((2-hydroxyethyl) amino) hexanoate (200 mg,0.61 mmol) were dissolved in acetonitrile (2 mL), potassium carbonate (251 mg, 1.82 mmol) and potassium iodide (20 mg,0.12 mmol) were added to the above system, and the reaction was heated to 70℃with stirring. After the reaction was completed, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (0-24% methanol/dichloromethane) to give YK-701-PM3 (50 mg, 0.11mmol, 17.8%). C (C) 26 H 53 NO 5 ,MS(ES): m/z(M+H + )460.4。
Step four: synthesis of 8, 8-dimethoxy pentadecane (YK-701-PM 4)
Pentadecan-8-one (500 mg, 2.21 mmol) was dissolved in methanol (10 mL), and pyridine p-toluenesulfonate (56 mg, 0.22 mmol) and trimethyl orthoformate (5 mL) were added to the above system, and the reaction was stirred at room temperature for 10 hours. After completion of the reaction, triethylamine (0.2 mL) and water (20 mL) were added, followed by extraction with ethyl acetate (15X 2), and the organic phases were combined, dried over anhydrous sodium sulfate, and the solution was removed by spin-drying under reduced pressure to give YK-701-PM4 (420 mg, 1.54mmol, 69.7%).
Step five: synthesis of undecyl 6- ((5- (2, 2-diheptyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) hexanoate (YK-701)
YK-701-PM3 (50 mg, 0.11 mmol) and YK-701-PM4 (200 mg,0.61 mmol) were dissolved in dichloromethane (3 mL), and p-toluenesulfonic acid monohydrate (2.1 mg, 0.01 mmol) was added to the above system and reacted at room temperature with stirring for 5 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (0-7% methanol/dichloromethane) to give YK-701 (35 mg, 0.05mmol, 48.1%). C (C) 41 H 81 NO 5 ,MS(ES): m/z(M+H + )668.6。
YK-701: 1 H NMR (400 MHz, CDCl 3 ) δ 4.07–4.00 (m, 3H), 3.84 (s, 2H), 3.47–3.39 (m, 1H), 2.97 (s, 2H), 2.88 (s, 3H), 2.32 (t, J=7.3 Hz, 2H), 1.80 – 1.52 (m, 13H), 1.45–1.19 (m, 46H), 0.88 (t, J=6.7 Hz, 9H).
Synthesis of undecyl 6- (((2, 2-didecyl-1, 3-dioxolan-4-yl) methyl) (2-hydroxyethyl) amino) hexanoate (YK-702) and undecyl 6- ((2-hydroxyethyl) ((2-tridecyl-1, 3-dioxolan-4-yl) methyl) amino) hexanoate (YK-703)
The synthetic route is as follows:
step one: synthesis of 11, 11-dimethoxy eicosane (YK-702-PM 1)
Using 11-di-undecanone (2.0 g, 6.44 mmol) as a starting material, YK-702-PM1 (798 mg, 2.24mmol, 34.8%) was obtained according to the method of YK-701-PM 4.
Step two: synthesis of undecyl 6- ((2, 3-dihydroxypropyl) (2-hydroxyethyl) amino) hexanoate (YK-702-PM 2)
With 6- ((2-hydroxyethyl)) Undecyl amino) hexanoate (200 mg,0.61 mmol) and 3-chloro-1, 2-propanediol (81 mg,0.73 mmol) were used as starting materials to give YK-702-PM2 (120 mg, 0.30mmol, 48.7%) according to the method of YK-701-PM 3. C (C) 22 H 45 NO 5 ,MS(ES): m/z(M+H + )404.3。
Step three: synthesis of undecyl 6- (((2, 2-didecyl-1, 3-dioxolan-4-yl) methyl) (2-hydroxyethyl) amino) hexanoate (YK-702)
YK-702 (40 mg,0.06mmol, 23.0%) was obtained by the method of YK-701 starting with YK-702-PM1 (707 mg,1.98 mmol) and YK-702-PM2 (100 mg, 0.25 mmol). C (C) 43 H 85 NO 5 , MS(ES): m/z(M+H + )696.7。
YK-702: 1 H NMR (400 MHz, CDCl 3 ) δ 4.31 (s, 1H), 4.18 – 3.99 (m, 3H), 3.66 (s, 2H), 3.57 – 3.46 (m, 1H), 2.78 (s, 6H), 2.38 – 2.28 (m, 2H), 1.69 – 1.58 (m, 8H), 1.39 – 1.25 (m, 52H), 0.96 – 0.86 (m, 9H).
Step four: synthesis of undecyl 6- ((2-hydroxyethyl) ((2-tridecyl-1, 3-dioxolan-4-yl) methyl) amino) hexanoate (YK-703)
YK-702-PM2 (100 mg, 0.25 mmol) and tetradecaldehyde (78.8 mg, 0.37 mmol) were used as starting materials to obtain YK-703 (25 mg,0.04mmol, 16.7%) according to the method of YK-701. C (C) 36 H 71 NO 5 , MS(ES): m/z(M+H + )598.5。
YK-703: 1 H NMR (400 MHz, CDCl 3 ) δ 4.95 (dt, J = 32.4, 4.7 Hz, 1H), 4.38 – 3.91 (m, 3H), 3.86 – 3.41 (m, 2H), 2.94 (s, 2H), 2.39 – 2.29 (m, 2H), 1.62 (dd, J = 15.2, 7.7 Hz, 6H), 1.48 – 1.25 (m, 48H), 0.89 (d, J = 6.5 Hz, 6H).
3.6 Synthesis of undecyl caproate (YK-704) - ((5- (2, 2-dinonyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino)
The synthetic route is as follows:
step one: synthesis of 10, 10-dimethoxy-nonadecane (YK-704-PM 1)
Using 10-nonadecanone (1.0 g, 3.54 mmol) as a raw material, YK-704-PM1 (1.0 g, 3.04mmol, 86.0%) was obtained according to the method of YK-701-PM 4.
Step two: synthesis of undecyl 6- ((5- (2, 2-dinonyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) hexanoate (YK-704)
YK-701-PM3 (120 mg, 0.26 mmol) and YK-704-PM1 (465 mg, 1.42 mmol) were used as raw materials to obtain YK-703 (30 mg,0.04mmol, 15.9%) according to the method of YK-701. C (C) 45 H 89 NO 5 , MS(ES): m/z(M+H + )724.7。
YK-704: 1 H NMR (400 MHz, Chloroform-d) δ 4.08 – 4.02 (m, 2H), 3.92 (s, 1H), 3.12 – 2.90 (m, 4H), 2.32 (t, J = 7.3 Hz, 2H), 1.79 (s, 2H), 1.60 (ddt, J = 22.5, 14.6, 6.8 Hz, 8H), 1.47 (d, J = 17.2 Hz, 2H), 1.41 – 1.22 (m, 58H), 0.88 (t, J = 6.6 Hz, 9H).
4.6 Synthesis of undecyl caproate (YK-705) - ((5- (2, 2-dioctyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino)
The synthetic route is as follows:
step one: synthesis of 9, 9-dimethoxy heptadecane (YK-705-PM 1)
Using 9-heptadecanone (500 mg, 1.96 mmol) as a raw material, YK-705-PM1 (500 mg, 1.66mmol, 84.9%) was obtained according to the method of YK-701-PM 4.
Step two: synthesis of undecyl 6- ((5- (2, 2-dioctyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) hexanoate (YK-705)
YK-705 (50 mg, 0.07mmol, 25.7%) was obtained by the method of YK-701 using YK-701-PM3 (130 mg, 0.28 mmol) and YK-705-PM1 (420 mg, 1.40 mmol) as raw materials. C (C) 43 H 85 NO 5 , MS(ES): m/z(M+H + )696.7。
YK-705: 1 H NMR (400 MHz, CDCl 3 ) δ 4.11 – 4.01 (m, 3H), 3.47 (d, J = 23.2 Hz, 1H), 3.18 (s, 1H), 3.07 (s, 2H), 2.40 – 2.31 (m, 2H), 1.86 (s, 2H), 1.67 – 1.54 (m, 8H), 1.44 – 1.24 (m, 56H), 0.88 (t, J = 6.6 Hz, 9H).
5.Synthesis of ethyl 12- (2- (4- ((2-hydroxyethyl) (6-oxo-6- (undecyloxy) hexyl) amino) butyl) -5-octyl-1, 3-dioxolan-4-yl) dodecanoate (YK-706)
The synthetic route is as follows:
step one: synthesis of ethyl 13-docosenoate (YK-706-PM 1)
13-docosanoic acid (2.0 g, 5.91 mmol) was dissolved in dichloromethane (20 mL), EDCI (1.3 g, 6.78 mmol), DMAP (72.2 mg,0.59 mmol) and ethanol (408 mg,8.9 mmol) were added sequentially. The reaction was stirred at room temperature for 8 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (0-5% ethyl acetate/n-hexane) to give YK-706-PM1 (1.5 g,4.09mmol, 69.2%).
Step two: synthesis of ethyl 13, 14-dihydroxybehenate (YK-706-PM 2)
YK-706-PM1 (1.0 g, 2.73 mmol) was dissolved in a mixed solution of THF (15 mL) and water (15 mL), potassium osmium (85 mg, 0.27 mmol), N-methylmorpholine-N-oxide (480 mg, 4.1 mmol) was added to the above solution in this order, and the reaction was stirred at room temperature overnight. After the reaction was completed, it was quenched with saturated aqueous sodium sulfite solution. After dilution with water (30 mL), extraction was performed with methylene chloride (30 mL. Times.3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-60% ethyl acetate/n-hexane) to give YK-706-PM2 (600 mg, 1.50mmol, 54.9%).
Step three: synthesis of ethyl 12- (2- (4-chlorobutyl) -5-octyl-1, 3-dioxolan-4-yl) dodecanoate (YK-706-PM 3)
YK-706-PM3 (120 mg,0.24mmol, 95.4%) was obtained by the synthetic method of YK-701 using YK-706-PM2 (100 mg, 0.25 mmol) and 5-chlorovaleraldehyde (30 mg, 0.25 mmol) as raw materials.
Step four: synthesis of ethyl 12- (2- (4- ((2-hydroxyethyl) (6-oxo-6- (undecyloxy) hexyl) amino) butyl) -5-octyl-1, 3-dioxolan-4-yl) dodecanoate (YK-706)
YK-706 (24 mg,0.03mmol, 14.3%) was obtained by the synthetic method of YK-701-PM3 starting from YK-706-PM3 (120 mg,0.24 mmol) and undecyl 6- ((2-hydroxyethyl) amino) hexanoate (70 mg, 0.21 mmol). C (C) 48 H 93 NO 7 , MS(ES): m/z(M+H + )796.7。
YK-706: 1 H NMR (400 MHz, CDCl 3 ) δ 4.87 (t, J = 4.3 Hz, 1H), 4.21 – 3.99 (m, 6H), 3.91 (d, J = 8.3 Hz, 2H), 3.28 – 3.03 (m, 5H), 2.31 (dt, J = 20.1, 7.4 Hz, 4H), 1.92 (brs, 4H), 1.72 – 1.57 (m, 8H), 1.55 – 1.36 (m, 10H), 1.34 – 1.20 (m, 46H), 0.88 (t, J = 6.7 Hz, 6H).
6.Synthesis of ethyl 8- (2- (4- ((2-hydroxyethyl) (6-oxo-6- (undecyloxy) hexyl) amino) butyl) -5-octyl-1, 3-dioxolan-4-yl) octanoate (YK-707)
The synthetic route is as follows:
step one: synthesis of ethyl oleate (YK-707-PM 1)
Using oleic acid (2.0 g, 7.08 mmol), EDCI (1.6 g, 8.35 mmol), DMAP (86 mg, 0.70 mmol), ethanol (326 mg, 7.0 mmol) as a starting material, YK-707-PM1 (1.9 g,6.12mmol, 86.4%) was obtained according to the synthetic method of YK-706-PM 1.
Step two: synthesis of ethyl 9, 10-dihydroxyoctadecanoate (YK-707-PM 2)
YK-707-PM2 (670 mg, 1.94mmol, 67.1%) was obtained by the synthesis method of YK-706-PM2 using YK-707-PM2 (900 mg, 2.90 mmol) as a raw material.
Step three: synthesis of ethyl 8- (2- (4-chlorobutyl) -5-octyl-1, 3-dioxolan-4-yl) octanoate (YK-707-PM 3)
YK-707-PM3 (180 mg, 0.40mmol, 51.6%) was obtained by the synthetic method of YK-701 using YK-707-PM2 (270 mg, 0.78 mmol) and 5-chlorovaleraldehyde (95 mg, 0.79 mmol) as raw materials.
Step four: synthesis of ethyl 8- (2- (4- ((2-hydroxyethyl) (6-oxo-6- (undecyloxy) hexyl) amino) butyl) -5-octyl-1, 3-dioxolan-4-yl) octoate (YK-707)
YK-707 (75 mg, 0.10mmol, 25.3%) was obtained by the synthetic method of YK-701-PM3 starting from YK-707-PM3 (180 mg, 0.40 mmol) and undecyl 6- ((2-hydroxyethyl) amino) hexanoate (224 mg, 0.68 mmol). C (C) 44 H 85 NO 7 ,MS(ES): m/z(M+H + )740.6。
YK-707: 1 H NMR (400 MHz, Chloroform-d) δ 4.86 (t, J = 4.4 Hz, 1H), 4.17 – 3.96 (m, 4H), 3.89 (s, 3H), 3.05 (s, 1H), 2.95 (s, 2H), 2.30 (dt, J = 12.1, 7.4 Hz, 4H), 1.89 – 1.73 (m, 3H), 1.73 – 1.56 (m, 8H), 1.55 – 1.21 (m, 52H), 0.88 (t, J = 6.7 Hz, 6H).
7. Synthesis of heptadec-9-yl-8- ((8- (2-decyl-5-octyl-1, 3-dioxolan-4-yl) octyl) (2-hydroxyethyl) amino) octanoate (YK-708) and heptadec-9-yl-8- ((2-hydroxyethyl) (8- (5-octyl-2-tridecyl-1, 3-dioxolan-4-yl) octyl) amino) octanoate (YK-709)
The synthetic route is as follows:
step one: synthesis of 1-bromooctadeca-9-ene (YK-708-PM 1)
Octadec-9-en-1-ol (3.0 g, 11.17 mmol) and triphenylphosphine (3.5 g, 13.34 mmol) were dissolved in dichloromethane (30 mL) and N-bromosuccinimide (2.4 g, 13.48 mmol) was added in portions to the above system and reacted at room temperature for 5 hours. The reaction solution was concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-6% ethyl acetate/n-hexane) to give YK-708-PM1 (3.0 g, 9.1mmol, 81.0%).
Step two: synthesis of 1-bromooctadecane-9, 10-diol (YK-708-PM 2)
YK-708-PM2 (260 mg, 0.71mmol, 47.1%) was obtained by the synthesis method of YK-706-PM2 using YK-708-PM1 (500 mg, 1.51 mmol) as a raw material.
Step three: synthesis of heptadec-9-yl 8- ((9, 10-dihydroxyoctadecyl) (2-hydroxyethyl) amino) octanoate (YK-708-PM 3)
YK-708-PM3 (170 mg, 0.23mmol, 52.0%) was obtained by the method for synthesizing YK-701-PM3 starting from YK-708-PM2 (200 mg, 0.55 mmol) and 8- ((2-hydroxyethyl) amino) heptadec-9-yl octanoate (197 mg, 0.45 mmol). C (C) 45 H 91 NO 5 , MS(ES): m/z(M+H + )726.7。
Step four: synthesis of heptadec-9-yl-8- ((8- (2-decyl-5-octyl-1, 3-dioxolan-4-yl) octyl) (2-hydroxyethyl) amino) octanoate (YK-708)
YK-708 (45 mg, 0.05mmol, 46.6%) was obtained by the synthetic method of YK-701 starting from YK-708-PM3 (80 mg,0.11 mmol) and undecalaldehyde (29 mg,0.17 mmol). C (C) 56 H 111 NO 5 , MS(ES): m/z(M+H + )878.9。
YK-708: 1 H NMR (400 MHz, CDCl 3 ) δ 4.90 – 4.82 (m, 1H), 3.90 (d, J = 6.8 Hz, 1H), 3.70 (s, 2H), 2.79 (s, 2H), 2.68 (s, 4H), 2.33-2.23(m, 2H), 1.64 – 1.18 (m, 86H), 0.89 – 0.85 (m, 12H).
Step five: synthesis of heptadec-9-yl-8- ((2-hydroxyethyl) (8- (5-octyl-2-tridecyl-1, 3-dioxolan-4-yl) octyl) amino) octanoate (YK-709)
YK-709 (35 mg, 0.04mmol, 34.6%) was obtained by the synthetic method of YK-701 using YK-708-PM3 (80 mg,0.11 mmol) and tetradecaldehyde (36 mg,0.17 mmol) as raw materials. C (C) 59 H 117 NO 5 , MS(ES): m/z(M+H + )920.9。
YK-709: 1 H NMR (400 MHz, CDCl 3 ) δ 4.89 – 4.83 (m, 1H), 3.90 (d, J = 7.6 Hz, 1H), 3.61 (t, J = 5.0 Hz, 2H), 2.68 (t, J = 4.9 Hz, 2H), 2.58 – 2.53 (m, 4H), 2.28 (t, J = 7.5 Hz, 2H), 1.73 – 1.03 (m, 92H), 0.91 – 0.83 (m, 12H).
8. Synthesis of heptadec-9-yl-8- ((12- (2-decyl-5-octyl-1, 3-dioxolan-4-yl) dodecyl) (2-hydroxyethyl) amino) octanoate (YK-710) and heptadec-9-yl-8- ((2-hydroxyethyl) (12- (5-octyl-2-tridecyl-1, 3-dioxolan-4-yl) dodecyl) amino) octanoate (YK-711)
The synthetic route is as follows:
step one: synthesis of 1-bromodocosa-9-ene (YK-710-PM 1)
The synthesis of YK-710-PM1 (1.13 g, 2.92mmol, 94.7%) was performed using docosa-9-en-1-ol (1.0 g, 3.08 mmol) and N-bromosuccinimide (641 mg, 3.60 mmol) as starting materials according to the method for YK-708-PM 1.
Step two: synthesis of 22-bromobehenate-9, 10-diol (YK-710-PM 2)
YK-710-PM2 (750 mg, 1.78mmol, 69.0%) was obtained by the synthesis method of YK-707-PM2 using YK-710-PM1 (1.0 g, 2.58 mmol) as a raw material.
Step three: synthesis of heptadec-9-yl 8- ((13, 14-dihydroxybehenyl) (2-hydroxyethyl) amino) octanoate (YK-710-PM 3)
Using YK-710-PM2 (287 mg, 0.68 mmol) and 8- ((2-hydroxyethyl) amino) heptadec-9-yl octanoate (250 mg, 0.57 mmol) as raw materials, YK-710-PM3 (200 mg, 0.26mmol, 44.9%) was obtained according to the synthetic method of YK-701-PM 3. C (C) 49 H 99 NO 5 ,MS(ES): m/z(M+H + )782.8。
Step four: synthesis of heptadec-9-yl-8- ((12- (2-decyl-5-octyl-1, 3-dioxolan-4-yl) dodecyl) (2-hydroxyethyl) amino) octanoate (YK-710)
YK-710 (89 mg, 0.10mmol, 73.3%) was obtained by the synthetic method of YK-701 starting with YK-710-PM3 (100 mg, 0.13 mmol) and undecalaldehyde (36 mg, 0.21 mmol). C (C) 60 H 119 NO 5 , MS(ES): m/z(M+H + )934.9。
YK-710: 1 H NMR (400 MHz, CDCl 3 ) δ 4.90 – 4.83 (m, 1H), 3.90 (d, J = 8.4 Hz, 1H), 3.59 (t, J = 5.1 Hz, 2H), 2.65 (t, J = 5.1 Hz, 2H), 2.57 – 2.45 (m, 4H), 2.28 (t, J = 7.5 Hz, 2H), 1.62 – 1.22 (m, 94H), 0.90 – 0.85 (m, 12H).
Step five: synthesis of heptadec-9-yl-8- ((2-hydroxyethyl) (12- (5-octyl-2-tridecyl-1, 3-dioxolan-4-yl) dodecyl) amino) octanoate (YK-711)
YK-711 (130 mg, 0.13mmol, 70.0%) was obtained by the synthesis method of YK-701 starting from YK-710-PM3 (150 mg, 0.19 mmol) and tetradecaldehyde (62 mg, 0.29 mmol). C (C) 63 H 125 NO 5 , MS(ES): m/z(M+H + )977.0。
YK-711: 1 H NMR (400 MHz, CDCl 3 ) δ 4.89 – 4.84 (m, 1H), 3.90 (d, J = 8.5 Hz, 1H), 3.55 (t, J = 5.3 Hz, 2H), 2.60 (t, J = 5.2 Hz, 2H), 2.50 – 2.43 (m, 4H), 2.27 (q, J = 7.6 Hz, 2H), 1.61 – 1.22 (m, 100H), 0.90 – 0.84 (m, 12H).
9.8 Synthesis of heptadec-9-yl ester of- ((5- (2-decyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) octanoate (YK-712) and heptadec-9-yl ester of 8- ((2-hydroxyethyl) (5- (2-tridecyl-1, 3-dioxolan-4-yl) amino) octanoate (YK-713)
The synthetic route is as follows:
step one: synthesis of 8- ((6, 7-dihydroxyheptyl) (2-hydroxyethyl) amino) octanoic acid-heptadec-9-yl ester (YK-712-PM 1)
YK-712-PM1 (150 mg, 0.26mmol, 53.5%) was obtained by the synthetic method of YK-701-PM3 starting from YK-701-PM2 (300 mg, 1.42 mmol) and 8- ((2-hydroxyethyl) amino) octanoic acid-heptadec-9-yl ester (215 mg, 0.49 mmol). C (C) 34 H 69 NO 5 ,MS(ES): m/z(M+H + )572.5。
Step two: synthesis of heptadec-9-yl 8- ((5- (2-decyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) octanoate (YK-712)
YK-712-PM1 (75 mg, 0.13 mmol) and undecalaldehyde (34 mg,0.20 mmol) as raw material, YK-712 (45 mg, 0.06mmol, 47.8%) was obtained according to the synthetic method of YK-701. C (C) 45 H 89 NO 5 , MS(ES): m/z(M+H + )724.7。
YK-712: 1 H NMR (400 MHz, CDCl 3 ) δ 4.89 – 4.82 (m, 1H), 4.34 – 3.84 (m, 2H), 3.78 – 3.70 (m, 1H), 3.52 – 3.36 (m, 1H), 2.88 – 2.66 (m, 4H), 2.32 – 2.22 (m, 2H), 1.62 – 1.19 (m, 68H), 0.89-0.86 (m, 9H).
Step three: synthesis of heptadec-9-yl 8- ((2-hydroxyethyl) (5- (2-tridecyl-1, 3-dioxolan-4-yl) amino) octoate (YK-713)
YK-713 (55 mg, 0.07mmol, 55.2%) was obtained by the synthetic method of YK-701 starting with YK-712-PM1 (75 mg, 0.13 mmol) and tetradecaldehyde (42 mg, 0.20 mmol). C (C) 48 H 95 NO 5 , MS(ES): m/z(M+H + )766.7。
YK-713: 1 H NMR (400 MHz, CDCl 3 ) δ 4.90 – 4.81 (m, 1H), 4.14 – 3.86 (m, 3H), 3.51 – 3.38 (m, 1H), 3.06 – 2.87(m, 4H), 2.32 – 2.23 (m, 2H), 1.88 – 1.00 (m, 74H), 0.89 – 0.86 (m, 9H).
10.8 Synthesis of heptadec-9-yl octanoate (YK-714) of- ((4- ((2-decyl-1, 3-dioxolan-4-yl) methoxy) -4-oxobutyl) (2-hydroxyethyl) amino)
The synthetic route is as follows:
step one: synthesis of ethylene oxide-2-yl-methyl-4-bromobutyrate (YK-714-PM 1)
Using 4-bromobutyric acid (2.0 g, 11.98 mmol) and ethylene oxide-2-yl methanol (806 mg,10.88 mmol) as starting materials, YK-714-PM1 (1.4 g, 6.28mmol, 57.7%) was obtained according to the synthesis of YK-707-PM 1.
Step two: synthesis of heptadec-9-yl 8- ((2-hydroxyethyl) (4- (oxiran-2-ylmethoxy) -4-oxobutyl) amino) octanoate (YK-714-PM 2)
With YK-714-PM1 (660 mg, 2.96 mmol) and 8- ((2-hydroxyethyl)) Amino) heptadec-9-yl octanoate (1.2 g, 2.72 mmol) was used as a starting material to obtain YK-714-PM2 (1.0 g, 1.71mmol, 63.0%) according to the method for synthesizing YK-701-PM 3. C (C) 34 H 65 NO 6 , MS(ES): m/z(M+H + )584.5。
Step three: synthesis of heptadec-9-yl 8- ((4- (2, 3-dihydroxypropoxy) -4-oxobutyl) (2-hydroxyethyl) amino) octanoate (YK-714-PM 3)
YK-714-PM2 (150 mg, 0.26 mmol) was used as a starting material, and YK-714-PM3 (154 mg, 0.26mmol, 98.4%) was obtained according to the method for synthesizing YK-701-PM 2. C (C) 34 H 67 NO 7 , MS(ES): m/z(M+H + ) 602.5。
Step four: synthesis of heptadec-9-yl 8- ((4- ((2-decyl-1, 3-dioxolan-4-yl) methoxy) -4-oxobutyl) (2-hydroxyethyl) amino) octanoate (YK-714)
YK-714 (40 mg, 0.05mmol, 20.4%) was obtained by the synthetic method of YK-701 starting with YK-714-PM3 (154 mg, 0.26 mmol) and undecalaldehyde (73 mg, 0.43 mmol). C (C) 45 H 87 NO 7 ,MS(ES): m/z(M+H + )754.7。
YK-714: 1 H NMR (400 MHz, CDCl 3 ) δ 4.92 – 4.81 (m, 1H), 4.35 – 4.06 (m, 3H), 3.98 – 3.52 (m, 4H), 2.94 – 2.72 (m, 5H), 2.48 – 2.41 (m, 2H), 2.28 (t, J = 6.4 Hz, 2H), 2.05 – 1.89(m, 2H), 1.72 – 1.17 (m, 58H), 0.94 – 0.82 (m, 9H).
11.8 Synthesis of heptadec-9-yl ester of- ((5- (2, 2-diheptyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) octanoate (YK-715)
The synthetic route is as follows:
/>
step one: synthesis of 8, 8-dimethoxy pentadecane (YK-715-PM 1)
YK-715-PM1 (2.7 g,9.91mmol, 97.5%) was obtained by the method for synthesizing YK-701-PM4 starting from pentadecan-8-one (2.3 g, 10.16 mmol).
Step two: synthesis of heptadec-9-yl 8- ((5- (2, 2-diheptyl-1, 3-dioxolan-4-yl) pentyl) (2-hydroxyethyl) amino) octanoate (YK-715)
YK-715 (35 mg, 0.04mmol, 12.1%) was obtained by synthesizing YK-701 from YK-715-PM1 (100 mg,0.37 mmol) and YK-712-PM1 (210 mg,0.37 mmol). C (C) 49 H 97 NO 5 , MS(ES): m/z(M+H + )780.7。
YK-715: 1 H NMR (300 MHz, CDCl 3 ) δ 4.86 (s, 1H), 4.03 (s, 2H), 3.71 (s, 2H), 3.46 (d, J = 13.8 Hz, 2H), 2.74 (d, J = 34.4 Hz, 6H), 2.28 (s, 3H), 1.68 – 1.46 (m, 10H), 1.43 – 1.12 (m, 58H), 0.88 (s, 12H).
12.6 Synthesis of decyl 6- ((8- (2-decyl-5-octyl-1, 3-dioxolan-4-yl) octyl) (2-hydroxyethyl) amino) hexanoate (YK-716)
The synthetic route is as follows:
step one: synthesis of 4- (8-bromooctyl) -2-decyl-5-octyl-1, 3-dioxolane (YK-716-PM 1)
YK-716-PM1 (400 mg, 0.77mmol, 59.0%) was obtained by the synthetic method of YK-701 using YK-708-PM2 (480 mg, 1.31 mmol) and undecalaldehyde (413 mg, 2.43 mmol) as raw materials.
Step two: synthesis of decyl 6- ((8- (2-decyl-5-octyl-1, 3-dioxolan-4-yl) octyl) (2-hydroxyethyl) amino) hexanoate (YK-716)
YK-716 (63 mg, 0.08mmol, 13.3%) was obtained according to the method for synthesizing YK-701-PM3 starting from decyl YK-M-082-PM1 (393 mg, 0.76 mmol) and decyl 6- ((2-hydroxyethyl) amino) hexanoate (200 mg, 0.63 mmol). C (C) 47 H 93 NO 5 ,MS(ES): m/z(M+H + )752.7。
YK-716: 1 H NMR (300 MHz, CDCl 3 ) δ 5.10 (t, J = 4.9 Hz, 1H), 4.06 (t, J= 6.8 Hz, 3H), 3.77 (br s, 4H), 2.74 - 2.90 (m, 6H), 2.32 (br t, J = 7.3 Hz, 2H), 1.60 - 1.69 (m, 10H), 1.47 (br d, J = 14.0 Hz, 10H), 1.23 - 1.35 (m, 48H), 0.88 (br t, J = 6.4 Hz, 9H).
13.8 Synthesis of undecyl- ((8, 8-bis (octyloxy) octyl) (2-hydroxyethyl) amino) octanoate (Compound 1)
The synthetic route is as follows:
step one: synthesis of 8-bromo-1-octanal (Compound 1-PM 1)
To a solution of 8-bromooctan-1-ol (10.0 g, 47.8 mmol) in DCM (200 mL) was added pyridinium chlorochromate (PCC) (15.5 g, 71.7 mmol). After stirring at 15 ℃ for 5 hours, the reaction mixture was filtered and concentrated in vacuo. The crude residue was purified by silica gel chromatography (2-20% EtOAc/petroleum ether) to give compound 1-PM1 (6.7 g, 32.3mmol, 67.7%).
Step two: synthesis of 8-bromo-1, 1-bis (octyloxy) octane (Compound 1-PM 2)
Using 8-bromooctanal (2.0 g, 9.66 mmol) and octan-1-ol (1.89 g, 14.51 mmol) as raw materials, compound 1-PM2 (1.96 g, 4.36mmol, 45.1%) was obtained according to the method of YK-701.
Step three: synthesis of undecyl 8- ((8, 8-bis (octyloxy) octyl) (2-hydroxyethyl) amino) octanoate (Compound 1)
Starting with compound 1-PM2 (1.00 g, 2.22 mmol) and undecyl 8- ((2-hydroxyethyl) amino) octanoate (1.19 g, 3.33 mmol), compound 1 (661 mg, 0.91mmol, 41.0%) was obtained according to the method of synthesis of YK-701-PM 3. C (C) 45 H 91 NO 5 , MS(ES): m/z(M+H + ) 726.7。
Compound 1: 1 H NMR (300 MHz, CDCl 3 ) δ 4.50 (t, J = 5.9 Hz, 1H), 4.06 (t, J = 6.8 Hz, 2H), 3.51-3.55 (br s, 4H), 3.31 – 3.60 (m, 2H), 2.55 (br t, J = 5.4 Hz, 2H), 2.43 (t ,J=7.4Hz , 4H), 2.25 (t ,J=7.6Hz ,2H), 1.55-1.65 (br d, J = 14.0 Hz, 10H), 1.23 - 1.45 (m, 53H), 0.88 (br t, J = 6.4 Hz, 9H).
example 2: preparation condition optimization of nano lipid particle (LNP preparation)
1. Vector (liposome) and mRNA ratio optimization
The cationic lipid compounds YK-702, YK-705, YK-712 and YK-716 synthesized in example 1 were dissolved in ethanol at a molar ratio of 49:10:39.5:1.5 with DSPC (Ai Weita (Shanghai) medical science, inc.), cholesterol (Ai Weita (Shanghai) medical science, inc.) and DMG-PEG2000, respectively, to prepare an ethanol lipid solution. And rapidly adding the ethanol lipid solution into a citrate buffer solution (pH=4-5) by an ethanol injection method, and swirling for 30s for later use. eGFP-mRNA (purchased from Shanghai laboratory reagent limited) was diluted in citrate buffer (ph=4-5) to obtain an aqueous mRNA solution. Liposomes were prepared from a volume of liposome solution and an aqueous solution of mRNA at a weight ratio of total lipid to mRNA of 5:1, 10:1, 15:1, 20:1, 30:1 and 35:1, respectively. Ultrasound was performed at 25℃for 15min (ultrasound frequency 40kHz, ultrasound power 800W). The obtained liposome was diluted to 10 times of volume with PBS, and subjected to ultrafiltration in a 300kDa ultrafiltration tube to remove ethanol. And then the volume is fixed to a certain volume by PBS to obtain the LNP preparation which uses the cationic lipid YK-702 (or YK-705, YK-712, YK-716)/DSPC/cholesterol/DMG-PEG 2000 (the molar ratio is 49:10:39.5:1.5) to encapsulate the eGFP-mRNA.
The results of cell transfection experiments show that the weight ratio of the vector to the mRNA is in the range of 10:1-30:1, and the vector has good transfection effect, wherein the transfection effect is preferably 15:1, the transfection effect is poor in the ratios of 5:1 and 35:1, and the mRNA cannot be carried by the ratio.
2. Cationic lipid and neutral lipid ratio optimization
LNP formulations encapsulating eGFP-mRNA were prepared according to the method in 1, with cationic lipid YK-702 (or YK-705, YK-712, YK-716) to neutral lipid DSPC molar ratios of 1:1, 3:1, 3.5:1, 4:1, 4.9:1, 10:1, 15:1 and 20:1, respectively.
As can be seen from the cell transfection experiment, the molar ratio of the cationic lipid to the neutral lipid is 1:1-15:1, and the transfection efficiency is 4.5:1.
3. Optimization of the proportion of Polymer conjugated lipid to Carrier (Liposome)
LNP formulations encapsulating eGFP-mRNA were prepared according to the method 1 with YK-702 (or YK-705, YK-712, YK-716) as the cationic lipid in the carrier, with 0.5%, 1.5%, 2.5%, 3.5%, 5%, 10% and 15% of the polymer conjugated lipid DMG-PEG2000 in the carrier molar ratios, respectively.
Cell transfection experiment results show that the polymer conjugated lipid accounts for 0.5% -10% of the carrier mole ratio, and has the transfection effect, and the transfection efficiency is highest when 1.5% and lowest when 10%.
4. Optimization of the ratio of the ingredients in the Carrier (Liposome)
LNP formulations encapsulating eGFP-mRNA were prepared according to the method in 1, with cationic lipid YK-702 (or YK-705, YK-712, YK-716), neutral lipid DSPC, structured lipid cholesterol, and polymer conjugated lipid DMG-PEG2000 molar ratios of 75:5:15:5, 65:8:25:2, 49:10:39.5:1.5, 45:10:43.5:1.5, 45:25:20:10, 40:10:48.5:1.5, 35:10:53.5:1.5, and 25:5:65:5, respectively.
As shown by cell transfection experiments, the cationic lipid, the neutral lipid, the structural lipid and the polymer conjugated lipid have good transfection effect in the ranges of the molar ratio of (35-49): (7.5-15): (35-55): (1-5), wherein the molar ratio of (45:10:43.5:1.5) and (49:10:39.5:1.5) and (45:10:43.5:1.5.
Example 3: LNP preparation of eGFP-mRNA cell transfection experiments
Cell resuscitating and passaging: 293T cells were resuscitated and passaged in petri dishes for culture to the desired cell numbers.
Seed plate: cells in the dishes were digested and counted, plated in 96-well plates at 1 ten thousand cells per well, plated in 12-well plates at 15 ten thousand cells per well, and cultured overnight until cells attached.
Cell transfection experiments: LNP preparations (cationic lipids in the vector were YK-702, YK-705, YK-712 or YK-716) containing 1.5. Mu.g of the eGFP-mRNA prepared in example 2 were added to the cell culture solution of 12-well plates, and after further culturing for 24 hours, the transfection efficiency of the samples was examined by fluorescence microscopy based on fluorescence intensity.
According to the experimental results, the preparation conditions of the nano lipid particles (LNP preparation) are finally determined: the ratio of the vector to the mRNA is 15:1; the molar ratio of the cationic lipid to the neutral lipid is 4.5:1; the polymer conjugated lipid accounts for 1.5% of the liposome; the molar ratio of cationic lipid, neutral lipid, structural lipid and polymer conjugated lipid was 45:10:43.5:1.5, and the following experiments produced nanolipid particles (LNP formulation) under this condition.
Example 4: preparation of nanolipid particles (LNP formulation) (optimal formulation)
TABLE 2 cationic lipid Structure
YK-701, YK-702, YK-703, YK-704, YK-705, YK-706, YK-707, YK-708, YK-709, YK-710, YK-711, YK-712, YK-713, YK-714, YK-715, YK-716 were synthesized in example 1.
The cationic lipids listed in Table 2 and YK-701 to YK-716 were dissolved in ethanol with respect to DSPC (Ai Weita (Shanghai) medical science Co., ltd.), cholesterol (Ai Weita (Shanghai) medical science Co., ltd.) and DMG-PEG2000 respectively at a molar ratio of 45:10:43.5:1.5 to prepare an ethanol lipid solution, and the ethanol lipid solution was rapidly added to a citrate buffer (pH=4 to 5) by an ethanol injection method, and vortexed for 30s for use. The eGFP-mRNA (purchased from Shanghai laboratory reagent Co., ltd.) or the Fluc-mRNA (purchased from Shanghai laboratory reagent Co., ltd.) was diluted in a citrate buffer (pH=4 to 5) to obtain an aqueous mRNA solution. Liposomes were prepared by mixing a volume of liposome solution with an aqueous solution of mRNA at a weight ratio of total lipid to mRNA of 15:1. Ultrasound was performed at 25℃for 15min (ultrasound frequency 40kHz, ultrasound power 800W). The obtained liposome was diluted to 10 times of volume with PBS, and subjected to ultrafiltration in a 300kDa ultrafiltration tube to remove ethanol. The mixture was then sized to volume with PBS to give LNP formulations using cationic lipid/DSPC/cholesterol/DMG-PEG 2000 (mol% 45:10:43.5:1.5) to encapsulate eGFP-mRNA or Fluc-mRNA. Lipofectamine 3000 transfection reagent is widely used for cell transfection at present, has very good transfection performance and excellent transfection efficiency, can improve cell activity, and is suitable for cell types difficult to transfect. Lipofectamine 3000 preparation of eGFP-mRNA or Fluc-mRNA was prepared by the method described in Lipofectamine 3000 (Ind. Ipomoea) in the Ind. Of Ultrafrican trade, inc. by selecting Lipofectamine 3000 transfection reagent for comparison.
Example 5: determination of nanolipid particle size and polydispersity index (PDI)
Particle size and Polydispersity (PDI) were determined using dynamic light scattering using a malvern laser particle sizer.
10 μl of liposome solution was taken, diluted to 1mL with RNase-free deionized water, and added to the sample cell, and each sample was repeatedly assayed 3 times. The measurement conditions are as follows: 90. scattering angle, 25 ℃. The test results are shown in Table 3:
TABLE 3 particle size and polydispersity index (PDI) of nanolipid particles
As can be seen from table 3, the nano lipid particles prepared in example 4 have particle diameters of 114-203 nm, and can be used for delivering mRNA:
wherein, the particle size of the particles prepared from YK-703 is the smallest and is 114.56nm; the particle size of the particles prepared from YK-711 was the largest, 203.22nm.
The polydispersity of all the nano lipid particles is between 10% and 25%, wherein the minimum is YK-701, which is 11.2%; the maximum is YK-710, 23.1%.
The morphology of the particles prepared from YK-702, YK-705, YK-712, YK-716 is also at a good level.
Example 6: in vitro validation of LNP delivery vehicle performance
Cell resuscitating and passaging: the procedure is as in example 3.
Seed plate: the procedure is as in example 3.
1. Fluorescence detection of Fluc-mRNA (transfection efficiency)
LNP preparations containing 0.3. Mu.g of Fluc-mRNA (LNP preparation carrier composition: cationic lipid, DSPC, cholesterol and DMG-PEG2000, molar ratio: 45:10:43.5:1.5, wherein cationic lipid is the cationic lipid listed in Table 2) were added to cell culture broth of 96-well plates, and after further incubation for 24 h, the corresponding reagents were added according to Gaussia Luciferase Assay Kit instructions, and the intensity of fluorescence expression per well was detected by IVIS fluorescence detection system. The chemical structures of the designed compounds and the representative cationic lipids of the prior art are shown in Table 2. The transfection efficiency of LNP formulations prepared from a series of cationic lipid compounds designed according to the application, and prior art cationic lipids, including SM-102, MC3, HHMA, DLin-K-C2-DMA and Compound 1, in cells is shown in Table 4.
TABLE 4 Fluc-mRNA fluorescence detection results
Analysis of experimental results:
(1) The compounds contemplated by the present application, including YK-702, YK-705, YK-712 and YK-716, have chemical structures that differ significantly from the cationic lipids typical of the prior art, such as SM-102, MC3 and HHMA; there are minor differences, such as DLin-K-C2-DMA and Compound 1.
The chemical structure of the compounds designed in this application is quite different and very different compared to the typical cationic lipids of the prior art SM-102, MC3 and HHMA (table 2). SM-102, MC3 and HHMA have no acetal structure, and the compounds designed by the application have five-membered ring acetal structures, and have larger differences among other groups.
The chemical structure of the compounds contemplated by the present application is less different than the cationic lipids comprising acetal structures of the prior art, such as DLin-K-C2-DMA and compound 1 (table 2). DLin-K-C2-DMA and the compound of the application all contain five-membered ring acetal structures, and other structures are slightly different; the acetal structure of the compound 1 is a common branched structure, but both the compound 1 and the compound designed by the application contain a hydroxyethyl tertiary amine structure.
(2) In a series of designed compounds, the LNP preparation prepared by YK-702, YK-705, YK-712 and YK-716 has highest cell transfection efficiency, and compared with the representative cationic lipid in the prior art, the LNP preparation has greatly different structures (SM-102, MC3 and HHMA) or very small structure difference (DLin-K-C2-DMA and compound 1), and the cell transfection efficiency is obviously improved. For example, YK-716 can be up to 6.73 times SM-102, 10.10 times 70.91 times HHMA for MC3, 16.84 times DLin-K-C2-DMA, 9.54 times Compound 1, and 12.41 times Lipofectamine 3000.
SM-102, MC3, HHMA, DLin-K-C2-DMA and Compound 1 are typical cationic lipids in the prior art, with good transfection properties.
As can be seen from Table 4, LNP preparations containing Fluc-mRNA prepared from YK-702, YK-705, YK-712 and YK-716 showed the strongest fluorescence absorption and RLU values of 5563052, 6512323, 9487230 and 10329850, respectively.
As can be seen from fig. 1 and 2, LNP formulations comprising eGFP-mRNA prepared from YK-702, YK-705, YK-712, YK-716 showed significantly enhanced cell transfection effects compared to the prior art representative cationic lipids, such as SM-102, MC3, HHMA, DLin-K-C2-DMA, compound 1 and Lipofectamine 3000.
The cell transfection efficiency of YK-702 can reach 3.63 times of SM-102, 38.19 times of MC3, 5.44 times of HHMA, 9.07 times of DLin-K-C2-DMA, 5.14 times of compound 1 and 6.68 times of Lipofectamine 3000, and the transfection efficiency is obviously improved.
The cell transfection efficiency of YK-705 can reach 4.24 times of SM-102, 44.70 times of MC3, 6.37 times of HHMA, 10.62 times of DLin-K-C2-DMA, 6.02 times of compound 1 and 7.82 times of Lipofectamine 3000, and the transfection efficiency is obviously improved.
The cell transfection efficiency of YK-712 can reach 6.18 times of SM-102, 65.12 times of MC3, 9.27 times of HHMA, 15.47 times of DLin-K-C2-DMA, 8.77 times of compound 1 and 11.40 times of Lipofectamine 3000, and the transfection efficiency is obviously improved.
The cell transfection efficiency of YK-716 can reach 6.73 times of SM-102, 70.91 times of MC3, 10.10 times of HHMA, 16.84 times of DLin-K-C2-DMA, 9.54 times of compound 1 and 12.41 times of Lipofectamine 3000, and the transfection efficiency is obviously improved.
The transfection efficiency of YK-710 cells was 0.96 times that of SM-102, 2.40 times that of DLin-K-C2-DMA and 1.36 times that of Compound 1, and the transfection efficiency was comparable.
The data were analyzed using GraphPad Prism software, and any of YK-702, YK-705, YK-712, and YK-716 was significantly different from SM-102, MC3, HHMA, DLin-K-C2-DMA, and Compound 1 and Lipofectamine 3000, with significantly improved transfection efficiency.
The cell transfection efficiency of LNP formulations prepared therefrom cannot be deduced from the structure of cationic lipid compounds, and is very likely to be very different, both from structurally different to structurally similar compounds.
(3) YK-702, YK-705 and YK-712 are similar to the structures and X 1 =O、X 2 =CH、R 3 =no substituent, R 4 Cell transfection efficiency was significantly improved compared to a series of compounds of =h. For example, YK-712 can be transfected with 380 times as efficiently as YK-703.
Will be of similar structure, X 1 =O、X 2 =CH、R 3 =no substituent, R 4 A series of compounds, e.g., YK-701, YK-703, YK-704, YK-713, YK-714 and YK-715, =H, were structurally different from YK-702, YK-705 and YK-712 only by slightly different individual groups (Table 1). Cell transfection results show that the activity of the series of compounds is very different, wherein the cell transfection efficiency of YK-702, YK-705 and YK-712 is the highest, and the cell transfection efficiency of YK-702 can reach 19.89 times of YK-701, 225.35 times of YK-703, 157.50 times of YK-704, 103.88 times of YK-713, 119.84 times of YK-714 and 252.51 times of YK-715 respectively. The cell transfection efficiency of YK-705 can reach 23.29 times of YK-701, 263.81 times of YK-703, 184.38 times of YK-704, 121.61 times of YK-713, 140.29 times of YK-714 and 295.60 times of YK-715 respectively. The cell transfection efficiency of YK-712 can reach 33.93 times of YK-701, 384.32 times of YK-703, 268.60 times of YK-704, 177.16 times of YK-713, 204.37 times of YK-714 and 430.63 times of YK-715 respectively, and the transfection efficiency is obviously improved.
(4) YK-716 is similar to structure and X 1 =O、X 2 =CH、R 2 =H、R 3 =no substituent group、R 4 = C 8 Compared with the linear alkyl compound, the cell transfection efficiency is obviously improved. For example, YK-716 can be transfected up to 44.48 times YK-711.
Similar to the structure, X 1 =O、X 2 =CH、R 2 =H、R 3 =no substituent, R 4 = C 8 Compared with the linear alkyl compounds YK-708, YK-709, YK-710 and YK-711 (table 1), the transfection efficiency of the YK-716 cells is obviously improved, and the transfection efficiency can reach 5.63 times, 11.97 times, 7.03 times and 44.48 times of the transfection efficiency of the YK-708, YK-709, YK-710 and YK-711 respectively.
(5) YK-716 is similar to structure and X 1 =CH、X 2 =O、R 1 =C 8 Straight chain alkyl or- (CH) 2 ) 7 C(O)OCH 2 CH 3 、R 2 =H、R 3 =C 8 Straight chain alkyl, R 4 Cell transfection efficiency was significantly improved compared to the compounds without substituents. For example, YK-716 can be transfected with 8.04 times as much cells as YK-706.
Similar to the structure, X 1 =CH、X 2 =O、R 1 =C 8 Straight chain alkyl or- (CH) 2 ) 7 C(O)OCH 2 CH 3 、R 2 =H、R 3 =C 8 Straight chain alkyl, R 4 Compared with YK-706 and YK-707 (table 1), the transfection efficiency of YK-716 cells is obviously improved and can reach 8.04 times and 3.92 times of YK-706 and YK-707 respectively.
The data were analyzed using GraphPad Prism software, and any of YK-702, YK-705, YK-712, and YK-716 showed significant differences compared to the other compounds, with significantly improved transfection efficiency.
2. Cell viability assay
LNP preparations containing 1.5. Mu.g of Fluc-mRNA (LNP preparation carrier composition: cationic lipid, DSPC, cholesterol and DMG-PEG2000, molar ratio: 45:10:43.5:1.5, wherein cationic lipid is the cationic lipid listed in Table 2) were added to cell culture broth of 96-well plates, after further culturing for 24 h, 10. Mu.L of CCK-8 solution was added to each well, and after incubating the plates in an incubator for 1 h, absorbance at 450nm was measured by a microplate reader, and cell viability results are shown in Table 5.
TABLE 5 cell survival
Analysis of experimental results:
(1) The series of compounds contemplated by the present application, including YK-702, YK-705, YK-711 and YK-716, have chemical structures that differ significantly from the prior art cationic lipids, such as SM-102, MC3 and HHMA; there are structural similarities, for example DLin-K-C2-DMA and Compound 1 (Table 2). LNP formulations prepared from YK-705 and YK-716 have minimal cytotoxicity and significantly improved cell viability compared to the cationic lipids typical of the prior art. For example, YK-705 cell viability may be 8% higher than SM-102, 14% higher than MC3, 24% higher than HHMA, 21% higher than DLin-K-C2-DMA, 14% higher than Compound 1, 61% higher than Lipofectamine 3000. The cytotoxicity of LNP formulations prepared therefrom cannot be speculated on the basis of the structure of cationic lipid compounds, and there is a strong possibility that the cytotoxicity to transfected cells is very different, whether they are structurally different or structurally similar compounds.
(2) Will be of similar structure, X 1 =O、X 2 =CH、R 3 =no substituent, R 4 A series of compounds, e.g., YK-701, YK-702, YK-703, YK-704, YK-713, YK-714 and YK-715, =H, differing only slightly in their individual groups compared to YK-705 (Table 1), showed a very large difference in cytotoxicity, with YK-705 having the highest cell viability, 44% higher than YK-701, 10% higher than YK-702, 24% higher than YK-703, 11% higher than YK-704, 8% higher than YK-713, 11% higher than YK-715, and significantly improved cell viability.
(4) Similar to the structure, X 1 =O、X 2 =CH、R 2 =H、R 3 =no substituent, R 4 = C 8 Compared with the compounds YK-708, YK-709, YK-710 and YK-711 (table 1), the linear alkyl compounds YK-716 have significantly improved survival rate, which can be 15% higher than that of YK-708, 8% higher than that of YK-709 and higher than that of YK-71023% higher than YK-711 by 10%.
(5) Similar to the structure, X 1 =CH、X 2 =O、R 1 =C 8 Straight chain alkyl or- (CH) 2 ) 7 C(O)OCH 2 CH 3 、R 2 =H、R 3 =C 8 Straight chain alkyl, R 4 Compared with YK-706 and YK-707 (Table 1), the cell survival rates of YK-705 and YK-716 are significantly improved by 24% and 23% respectively, and 31% and 30% respectively, higher than that of YK-706. (FIG. 3)
Example 7: in vivo validation of cationic Lipid (LNP) delivery vehicle performance
It was verified that delivery vectors prepared from the cationic lipids designed according to the present application, e.g., YK-712 and YK-716, are enriched in mouse liver and spleen, and that the delivered mRNA is significantly increased in mouse liver and spleen protein expression compared to the prior art cationic lipids. In vivo experiments further demonstrate that LNP delivery vectors prepared from the cationic lipids contemplated by the present application can efficiently deliver mRNA into animals and be expressed efficiently in the liver and spleen.
LNP preparations containing 10. Mu.g of Fluc-mRNA were injected into female BALB/C mice of 17-19 g weight, 4-6 weeks old, via tail vein, and the mice were given intraperitoneal injection of fluorography substrate at a specific time point (6 h) after administration, and the mice were free to move for 5 min, and then the average radiation intensity (corresponding to fluorescence expression intensity) of the protein expressed in the mice by the mRNA carried by LNP was detected by IVIS Spectrum small animal in vivo imager. After sampling, the mice were euthanized with carbon dioxide, dissected, and the internal organs of the mice were precisely isolated: heart, liver, spleen, lung, kidney. The average radiation intensity (corresponding to fluorescence expression intensity) of the mRNA carried by LNP in the protein expressed by each organ of the mice was measured by IVIS Spectrum small animal in vivo imaging instrument, and the results of the in vivo imaging measurement of the mice are shown in Table 6.
TABLE 6 in vivo imaging experimental data at a specific time point (6 h) after mouse dosing
Analysis of experimental results:
(1) LNP formulations prepared from YK-712 and YK-716, delivered mRNA levels expressed in the liver and spleen of mice, and in particular in the spleen, were significantly increased compared to the representative cationic lipids of the prior art. For example, YK-712 and YK-716 can be expressed in the spleen of mice up to 6.52-fold and 6.79-fold, respectively, of SM-102. mRNA was consistent with the results of cell transfection in example 6 in terms of mouse liver and spleen expression.
The spleen is the largest secondary lymphoid organ in the animal body, and the mRNA vaccine can rapidly induce immune response and generate antibodies in the body by improving the expression level of the delivered mRNA in the spleen. Can obviously improve the prevention effect without changing the vaccine components, and has important clinical significance.
In addition, LNP preparations containing Fluc-mRNA prepared from all compounds showed very large differences in expression in different organs of mice, YK-712, YK-716 and SM-102 were expressed in the liver and spleen, but not in other organs such as heart, lung and kidney. (FIG. 4).
(2) LNP preparations prepared from YK-712 and YK-716 showed the highest expression intensity of mRNA in the liver and spleen of mice compared to the compound YK-704, which was similar in structure and slightly different in individual groups. For example, YK-712 can be expressed in liver and spleen in 237.23-fold and 312.86-fold, respectively, and YK-716 can be expressed in liver and spleen in 242.76-fold and 325.87-fold, respectively, of YK-704. mRNA was consistent with cell transfection activity in terms of expression in mice.
In summary, the present application contemplates a series of cationic lipid compounds, e.g., YK-702, YK-705, YK-712, and YK-716, with significantly improved cell transfection efficiency, significantly reduced cytotoxicity, and significantly improved mRNA expression in the mouse spleen.
1. A series of compounds were designed, including YK-702, YK-705, YK-712 and YK-716, with chemical structures that were greatly different from the cationic lipids typical of the prior art, such as SM-102, MC3 and HHMA; there are structural similarities, such as DLin-K-C2-DMA and Compound 1.
2. In the designed series of compounds, LNP formulations prepared from YK-702, YK-705, YK-712 and YK-716 have significantly improved cell transfection efficiency, significantly reduced cytotoxicity and significantly improved mRNA expression in mouse liver and spleen compared to the cationic lipids typical in the prior art (including greatly different structures and similar structures). For example, cell transfection efficiency YK-716 can be up to 6.73 times that of SM-102, 70.91 times that of MC3, 10.10 times that of HHMA, 16.84 times that of DLin-K-C2-DMA, 9.54 times that of Compound 1, and 12.41 times that of Lipofectamine 3000; cell viability YK-705 was 8% higher than SM-102, 14% higher than MC3, 24% higher than HHMA, 21% higher than DLin-K-C2-DMA, 14% higher than Compound 1, 61% higher than Lipofectamine 3000; mRNA was expressed in the spleen of the mice, and YK-716 was 6.79 times as much as SM-102.
3. In a series of compounds with small chemical structure difference, LNP preparations prepared from YK-702, YK-705, YK-712 and YK-716 have remarkably improved cell transfection efficiency, remarkably reduced cytotoxicity and remarkably improved expression level of mRNA in mouse spleen compared with other compounds. For example, YK-716 cells can be transfected with 418.45 times of YK-703 and 468.88 times of YK-715, cytotoxicity can be reduced by 43% compared with YK-701, and mRNA expression in spleen of mice can be up to 325.87 times of YK-704.
4. Through unique design and screening, the application discovers that certain compounds, such as YK-702, YK-705, YK-712 and YK-716, can improve the delivery efficiency with remarkably improved cell transfection efficiency, remarkably reduced cytotoxicity and remarkably improved expression level in the spleen of an animal body compared with other compounds with similar structures in the prior art, and has unexpected technical effects.
The present application has been described in detail with the purpose of enabling those skilled in the art to understand the contents of the present application and to implement the same, but not to limit the scope of the present application, and all equivalent changes or modifications made according to the spirit of the present application should be covered in the scope of the present application.
Claims (68)
1. A compound of formula (I)
Or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
G 1 Is unsubstituted C 1~12 Alkylene or- (CH) 2 ) 3 C(O)OCH 2 -;
G 2 Is C 3~7 An alkylene group;
G 3 is C 2~3 An alkylene group;
R 1 is hydrogen atom, C 6~14 Straight chain alkyl, - (CH) 2 ) 11 C(O)OCH 2 CH 3 Or- (CH) 2 ) 7 C(O)OCH 2 CH 3 ;
R 2 Is a hydrogen atom or C 6~14 A linear alkyl group;
R 3 is unsubstituted, hydrogen, or C 6~14 A linear alkyl group;
R 4 is unsubstituted, hydrogen, or C 6~14 A linear alkyl group;
R 5 is C 6~15 Straight chain alkyl or C 10~22 Branched alkyl;
X 1 and X 2 Respectively a methine group or an oxygen atom.
2. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein G 1 Is unsubstituted C 1 Alkylene, C 5 Alkylene, C 8 Alkylene, C 4 Alkylene or C 12 An alkylene group.
3. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein G 2 Is C 5 Alkylene or C 7 An alkylene group.
4. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereofOr stereoisomers, wherein G 3 Is C 2 An alkylene group.
5. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 Is C 10 、C 8 、C 7 、C 9 Or C 13 A linear alkyl group.
6. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 2 Is a hydrogen atom.
7. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 2 Is C 10 、C 8 、C 7 Or C 9 A linear alkyl group.
8. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 3 Is unsubstituted.
9. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 3 Is C 7~12 A linear alkyl group.
10. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to claim 9, wherein R 3 Is C 8 A linear alkyl group.
11. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 4 Is a hydrogen atom.
12. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 4 Is C 7~12 A linear alkyl group.
13. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to claim 12, wherein R 4 Is C 8 A linear alkyl group.
14. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 4 Is unsubstituted.
15. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 5 Is C 11 Or C 10 A linear alkyl group.
16. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 5, wherein R 5 Is C 17 Branched alkyl groups.
17. A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to claim 16, wherein R 5 Is that
18. A compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 Is a methine group.
19. A compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 Is an oxygen atom.
20. A compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 2 Is a methine group.
21. A compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 2 Is an oxygen atom.
22. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) has one of the following structures:
23. The compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, wherein the compound of formula (I) is compound YK-702 having the structure:
24. the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) is compound YK-705 having the structure:
25. the compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) is compound YK-712 having the structure:
26. the compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, wherein the compound of formula (I) is compound YK-716 having the structure:
27. a composition comprising a carrier comprising a cationic lipid comprising a compound of formula (I) according to any one of claims 1-26, or a pharmaceutically acceptable salt or stereoisomer thereof.
28. The composition of claim 27, wherein the cationic lipid comprises 25% to 75% of the carrier by mole.
29. The composition of claim 27, wherein the carrier further comprises a neutral lipid.
30. The composition of claim 29, wherein the molar ratio of the cationic lipid to the neutral lipid is from 1:1 to 15:1.
31. The composition of claim 30, wherein the molar ratio of the cationic lipid to the neutral lipid is 4.5:1.
32. The composition of claim 29, wherein the neutral lipid comprises one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramides, sterols, and derivatives thereof.
33. The composition of claim 32, wherein the neutral lipid is selected from one or more of the following: 1, 2-Dioleoyl-sn-glycero-3-phosphorylcholine (DLPC), 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine (DMPC), 1, 2-dioleoyl-sn-glycero-3-phosphorylcholine (DOPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphorylcholine (DPPC), 1, 2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC), 1, 2-dioleoyl-sn-glycero-phosphorylcholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine (POPC), 1, 2-dioleoyl-octadecenyl-sn-glycero-3-phosphorylcholine (18:0) 1-oleoyl-2-cholesteryl hemisuccinyl-sn-3-phosphorylcholine (OChems PC), 1-hexadecyl-sn-glycero-3-phosphorylcholine (C16), 1, 2-dioleoyl-sn-glycero-3-phosphorylcholine (DUPC), 1, 2-dioleoyl-glycero-3-phosphorylcholine, 1-dioleoyl-2-glycero-3-phosphorylcholine (POPC), 1, 2-dioleoyl-sn-glycero-3-phosphate ethanolamine (DOPE), 1, 2-di-phytanoyl-sn-glycero-3-phosphate ethanolamine (ME 16.0 PE), 1, 2-di-stearoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-oleoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-linolenoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-arachidonoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-di-docosahexaenoyl-sn-glycero-3-phosphate ethanolamine, 1, 2-dioleoyl-sn-glycero-3-phosphate sodium salt (DOPG) dipalmitoyl phosphatidylglycerol (DPPG), palmitoyl phosphatidylethanolamine (POPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylethanolamine (DMPE), 1-stearoyl-2-oleoyl-stearoyl ethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyl-based phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE) and mixtures thereof.
34. The composition of claim 33, wherein the neutral lipid is DOPE and/or DSPC.
35. The composition of claim 27, wherein the carrier further comprises a structural lipid.
36. The composition of claim 35, wherein the molar ratio of the cationic lipid to the structural lipid is from 0.6:1 to 3:1.
37. The composition of claim 35, wherein the structural lipid is selected from one or more of the following: cholesterol, non-sterols, sitosterols, ergosterols, campesterols, stigmasterols, brassicasterol, lycorine, ursolic acid, alpha-tocopherol, corticosteroids.
38. The composition of claim 37, wherein the structural lipid is cholesterol.
39. The composition of claim 27, wherein the carrier further comprises a polymer conjugated lipid.
40. The composition of claim 39, wherein the polymer conjugated lipid comprises 0.5% to 10% of the carrier by mole.
41. The composition of claim 40, wherein the polymer conjugated lipid comprises 1.5% of the carrier by mole.
42. The composition of claim 39, wherein the polymer conjugated lipid is selected from one or more of the following: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol.
43. The composition of claim 42, wherein the polymer conjugated lipid is selected from one or more of the following: distearoyl phosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG 2000), dimyristoylglycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG 2000) and methoxypolyethylene glycol ditetradecylamide (ALC-0159).
44. The composition of claim 27, wherein the carrier comprises neutral lipids, structural lipids, and polymer conjugated lipids in a molar ratio of (25-75): 5-25): 15-65): 0.5-10.
45. A composition according to claim 44, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer conjugated lipid is (35-49): 7.5-15): 35-55): 1-5.
46. The composition of claim 45, wherein the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer conjugated lipid is 45:10:43.5:1.5.
47. The composition of claim 27, wherein the composition is a nanoparticle formulation having an average particle size of 10nm to 300nm; the polydispersity of the nanoparticle preparation is less than or equal to 50 percent.
48. The composition of claim 47, wherein the composition is a nanoparticle formulation having an average particle size of 90nm to 280nm; the polydispersity of the nanoparticle preparation is less than or equal to 45 percent.
49. The composition of claim 27, wherein the cationic lipid further comprises one or more other ionizable lipid compounds.
50. The composition of claim 27, further comprising a therapeutic or prophylactic agent.
51. The composition of claim 50, wherein the mass ratio of the carrier to the therapeutic or prophylactic agent is from 10:1 to 30:1.
52. The composition of claim 51, wherein the mass ratio of the carrier to the therapeutic or prophylactic agent is 12.5:1 to 20:1.
53. The composition of claim 52, wherein the mass ratio of the carrier to the therapeutic or prophylactic agent is 15:1.
54. The composition of claim 50, wherein the therapeutic or prophylactic agent comprises one or more of a nucleic acid molecule, a small molecule compound, a polypeptide, or a protein.
55. The composition of claim 50, wherein the therapeutic or prophylactic agent is a vaccine or compound capable of eliciting an immune response.
56. The composition of claim 54, wherein the therapeutic or prophylactic agent is a nucleic acid.
57. The composition of claim 56, wherein said therapeutic or prophylactic agent is ribonucleic acid (RNA).
58. The composition of claim 56, wherein said therapeutic or prophylactic agent is deoxyribonucleic acid (DNA).
59. The composition of claim 57, wherein the RNA is selected from the group consisting of: small interfering RNAs (siRNA), asymmetric interfering RNAs (aiRNA), micrornas (miRNA), dicer-substrate RNAs (dsRNA), small hairpin RNAs (shRNA), messenger RNAs (mRNA), and mixtures thereof.
60. The composition of claim 59, wherein the RNA is mRNA.
61. The composition of any one of claims 27-60, wherein the composition further comprises one or more pharmaceutically acceptable excipients.
62. Use of a compound of formula (I) according to any one of claims 1 to 26 or a pharmaceutically acceptable salt or stereoisomer thereof or a composition according to any one of claims 27 to 61 for the preparation of a nucleic acid medicament, a genetic vaccine, a small molecule medicament, a polypeptide or a protein medicament.
63. Use of a compound of general formula (I) as defined in any one of claims 1 to 26 or a pharmaceutically acceptable salt or stereoisomer thereof or a composition as defined in any one of claims 27 to 61 for the manufacture of a medicament for the treatment of a disease or condition in a mammal in need thereof, wherein the disease or condition is selected from the group consisting of: infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases and metabolic diseases.
64. The use according to claim 63, wherein the infectious disease is selected from the group consisting of: diseases caused by coronavirus, influenza virus or HIV virus, pediatric pneumonia, rift valley fever, yellow fever, rabies, or various herpes.
65. The use of any one of claims 63-64, wherein the mammal is a human.
66. The use of any one of claims 63-64, wherein the medicament is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.
67. The use of claim 66, wherein the composition is administered subcutaneously.
68. The use of any one of claims 63-64, wherein a dose of 0.001mg/kg to 10mg/kg of the medicament is administered to the mammal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310821280.1A CN116535381B (en) | 2023-07-06 | 2023-07-06 | Cationic lipid compound having five-membered ring acetal structure, composition containing same and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310821280.1A CN116535381B (en) | 2023-07-06 | 2023-07-06 | Cationic lipid compound having five-membered ring acetal structure, composition containing same and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116535381A CN116535381A (en) | 2023-08-04 |
CN116535381B true CN116535381B (en) | 2023-10-17 |
Family
ID=87449223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310821280.1A Active CN116535381B (en) | 2023-07-06 | 2023-07-06 | Cationic lipid compound having five-membered ring acetal structure, composition containing same and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116535381B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200599B1 (en) * | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
CN101346468A (en) * | 2005-06-15 | 2009-01-14 | 麻省理工学院 | Amine-containing lipids and uses thereof |
WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
CN104159615A (en) * | 2011-12-12 | 2014-11-19 | 协和发酵麒麟株式会社 | Lipid nanoparticles containing combinations of cationic lipids |
WO2017201349A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
CN107879960A (en) * | 2013-03-08 | 2018-04-06 | 诺华股份有限公司 | For transmitting the lipid and lipid composition of active component |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100055169A1 (en) * | 2008-04-16 | 2010-03-04 | Abbott Laboratories | Cationic lipids and uses thereof |
-
2023
- 2023-07-06 CN CN202310821280.1A patent/CN116535381B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200599B1 (en) * | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
CN101346468A (en) * | 2005-06-15 | 2009-01-14 | 麻省理工学院 | Amine-containing lipids and uses thereof |
WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
CN104159615A (en) * | 2011-12-12 | 2014-11-19 | 协和发酵麒麟株式会社 | Lipid nanoparticles containing combinations of cationic lipids |
CN107879960A (en) * | 2013-03-08 | 2018-04-06 | 诺华股份有限公司 | For transmitting the lipid and lipid composition of active component |
WO2017201349A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
Also Published As
Publication number | Publication date |
---|---|
CN116535381A (en) | 2023-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114957027B (en) | Cationic lipid compound, composition containing cationic lipid compound and application of cationic lipid compound | |
CN113993839B (en) | Ionizable lipid molecule, preparation method thereof and application thereof in preparation of lipid nanoparticles | |
WO2022166213A1 (en) | Ionizable lipid molecule, preparation method therefor, and application thereof in preparation of lipid nanoparticle | |
CN115784921B (en) | Extrahepatic targeting high-efficiency low-toxicity cationic lipid compound and composition thereof | |
CN115745820B (en) | Novel long-acting low-toxicity cationic lipid compounds and compositions thereof | |
CN114890907B (en) | Cationic lipid compound and preparation method and application thereof | |
CN114716355A (en) | Lipid compound, composition containing same and application | |
CN115403474A (en) | Lipid compounds and their use in nucleic acid delivery | |
CN116082275B (en) | Spleen high-expression cationic lipid compound, composition containing same and application | |
CN116178193B (en) | High-efficiency low-toxicity and stable-expression cationic lipid compound and composition thereof | |
CN115677518B (en) | Ionizable cationic lipid compounds and compositions for delivery of nucleic acids and uses | |
KR102560772B1 (en) | Novel ionizable lipids and lipid nanoparticle compositions thereof | |
CN117582452A (en) | Use of metal ions for promoting lysosome escape of active ingredient | |
CN116535381B (en) | Cationic lipid compound having five-membered ring acetal structure, composition containing same and use | |
CN117229160B (en) | Triester cationic lipid compounds, compositions containing same and uses thereof | |
CN118184538B (en) | Lung high-expression cationic lipid compound, composition containing same and application | |
CN118388360A (en) | Long-acting spleen-targeted cationic lipid compound containing benzene ring structure, composition containing long-acting spleen-targeted cationic lipid compound and application of long-acting spleen-targeted cationic lipid compound | |
CN118125947A (en) | Low-toxicity spleen-targeted cationic lipid compound containing carbamate structure, composition containing low-toxicity spleen-targeted cationic lipid compound and application of low-toxicity spleen-targeted cationic lipid compound | |
TWI849685B (en) | Cationic lipid compound, composition containing same and application | |
KR20240125981A (en) | Cationic lipid compounds, compositions containing same, and uses thereof | |
CN116589435A (en) | Ionizable lipids and compositions thereof for nucleic acid delivery | |
CN117567301A (en) | Cationic lipid molecules and their use in the preparation of lipid nanoparticle systems | |
CN117384055A (en) | Ionizable lipids for delivery of therapeutic agents and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40092608 Country of ref document: HK |